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ABSTRACT 
ENVIRONMENTAL REGULATION OF CARDIOVASCULAR DISEASE RISK AND 
REGENERATIVE CAPACITY 
Natasha Krystal DeJarnett 
April 11, 2013 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
the U.S., and its prevalence is predicted to increase through 2030. Acute and chronic 
exposure to fine particulate matter (PM2.5) and traffic pollution is positively associated 
with cardiovascular morbidity and mortality. It has been recently shown that exposure to 
elevated levels of combustion pollutants including tobacco smoke and PM2.5 is associated 
with decreased circulating levels of vascular progenitor cells (VPCs), angiogenic cells 
that participate in vascular repair and regeneration. Several investigators have reported 
that decreased VPC levels is associated with an increase in CVD risk and endothelial 
dysfunction (a decrease in vasodilatation), which is a key feature in atherosclerosis. 
Nevertheless, the mechanisms by which combustion pollutants affect VPC levels remains 
unclear, and the contribution of pollutant-induced VPC depletion to elevated CVD risk 
has not been assessed. This dissertation investigates how exposure to environmental 
pollution is associated with VPC levels in a population with increased CVD risk. 
The first chapter assesses 15 phenotypically distinct VPC populations with 
different angiogenic potential to describe the association between VPC levels and CVD 
risk factors, the Framingham Risk Score (FRS), and markers of thrombosis (fibrinogen 
vi 
and platelet mononuclear cell aggregates) and inflammation (high sensitivity C-reactive 
protein (hsCRP)). The second chapter describes the association between acrolein 
exposure (a combustion pollutant) and VPC levels, a novel assessment in human subjects. 
To understand the vascular effects of exposure to traffic pollution, the association 
between roadway proximity and VPC levels was evaluated in the third chapter. Together, 
these investigations suggest that VPCs may be a mechanistic link between CVD risk and 
environmental exposures. Results from these investigations may drive future mechanistic 
explorations, as well as targeted diagnostic examinations and prevention interventions.  
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1 
OVERALL BACKGROUND 
Public Health Burden 
Cardiovascular disease (CVD) is a class of non-infectious diseases of the 
circulatory system, affecting the heart or blood vessels 
1
. Some CVD conditions include 
myocardial infarction, stroke, and heart failure. CVD is the top cause of death both 
globally and in the U.S. 
1, 2
. The U.S. CVD prevalence in adults ≥ 20 years of age was 
35.3% in 2010 
1
. From 2007–2009, Kentucky was ranked seventh highest in the nation 
for CVD mortality, with a rate of 281.2 per 100,000, exceeding the U.S. mortality rate of 
243.9 per 100,000 population 
1
. In 2009, 32.3% of deaths were attributed to CVD, 
representing nearly 1 in every 3 deaths. Between 1999 and 2009, an average of 2,150 
people in the U.S. died daily from CVD (1 death per every 40 seconds) 
1
. Coronary artery 
disease (CAD; disease affecting the vessels that supply the heart) is the top cause of CVD 
mortality, responsible for 45% of CVD deaths 
3
. Though CVD mortality rates have 
declined in recent decades, the burden of CVD remains high. In addition to the heavy 
public health burden of CVD, it also carries a substantial economic burden. The total 
estimated cost of CVD in the U.S. for 2009 was $312.6 billion in direct and indirect costs 
(much greater, by comparison, than the $228 billion for cancer costs in 2008) 
1
. The 
national health and economic burden of CVD drives interest in CVD prevention. 
Although CVD burden is high, most CVD conditions are preventable through 
lifestyle choices including diet, physical activity, and cigarette smoking. Results from the 
Nurses’ Health Study cohort indicated that 82% of coronary events were attributed to 
2 
modifiable CVD risk factors, including proper diet and body weight, regular physical 
activity, abstaining from smoking, and moderate alcohol consumption; but only 3% of 
study subjects were considered low risk among all of those factors 
4
. Additionally, it is 
estimated that 63% of heart attacks and 31% of strokes could be prevented by eliminating 
modifiable risk factors 
5
. This emphasizes the need to investigate modifiable risk factors 
for CVD development to identify opportunities for prevention. 
Risk Factors 
Non-modifiable risk factors for CVD are ethnicity, gender, age, and heredity. 
African Americans have higher CVD mortality rates than Caucasians, and men have 
higher death rates from CVD than women. In 2009 the age-adjusted CVD mortality rates 
were 387.0 per 100,000 population for African American males, 281.4 per 100,000 
population for Caucasian males, 267.9 per 100,000 population for African American 
females, and 190.4 per 100,000 population for Caucasian females 
1
. As age increases, 
CVD incidence and mortality risk increase. As much as 83% of CAD mortality occurs at 
or above the age of 65 years 
6
. It has been estimated that persons with a first-degree 
relative (parent, sibling, or child) that had a heart attack before age 55 in men and 65 in 
women have about a 2-fold increased risk of cardiovascular events 
7
. 
Traditional independent, modifiable risk factors for CVD include age, gender, 
hypertension (high blood pressure), hypercholesterolemia (high blood cholesterol), 
diabetes mellitus, and cigarette smoking 
8
. Hypertension increases CVD risk because 
narrowed blood vessels cause the heart to work harder to pump blood to the body 
9
. Nine 
out of 10 people 40 years or older with hypertension are expected to develop CVD in 
their lifetime 
8, 10
. People with hypercholesterolemia, total blood cholesterol levels of 
3 
240mg or greater, have a 2-fold increased risk of heart attack, and that risk grows to 4-
fold with cholesterol levels of 300mg or greater 
11
. It is estimated that a 10% population-
wide reduction in blood cholesterol would result in a 30% decrease in CAD incidence 
12
. 
Diabetes mellitus is associated with a 2– to 3– times higher risk for developing CAD 13. 
Cigarette smokers have been reported to be 2–4 times more likely to develop CAD than 
nonsmokers 
14
.  Additionally, among people who had ever smoked cigarettes, 58% 
reported having 3 or more circulatory diseases 
15
.  
Additional risk factors include physical inactivity and obesity. Physical inactivity 
is estimated to contribute toward 12.2% of the global burden of myocardial infarctions 
16
. 
Additionally, physical inactivity has been shown to double the risk of developing CAD 
17
. Physical inactivity also contributes to overweight and obese conditions. People who 
are overweight or obese are believed to be more at risk for CVD because weight 
increases cause the heart to work harder delivering oxygen-rich blood to the body 
11
. 
Overweight men (body mass index ((BMI) ≥ 25) with CVD have been found to be more 
at risk for CVD mortality than normal weight (BMI ≤ 25) men with CVD 18. Overweight 
status in men and women has been associated with increased age-adjusted relative risks 
for CVD of 1.21 and 1.20, respectively 
19
. Additionally, being overweight is associated 
with population attributable risks of 23% (men) and 15% (women) for CAD 
19
. Nine to 
13% of total CVD mortality has been attributed to obesity (BMI ≥ 30) 20.  
The Framingham Risk Score (FRS) is a risk algorithm created from a longitudinal 
study in Framingham, MA, calculated using the traditional CVD risk factors including 
age, gender, hypertension, cholesterol, smoking, and diabetes. The FRS is commonly 
used in clinical practice to predict patients’ risk of future adverse CAD – myocardial 
4 
infarction or cardiac mortality 21. The FRS only predicts CAD events, not other 
conditions including stroke and heart failure. Criticism of the FRS suggests that the score 
is less accurate for predicting risk in women and populations with intermediate FRS 
levels (FRS 10–20) 22. The FRS only assesses people who do not have CAD, primary 
preventive individuals. To account for the secondary prevention population, the risk score 
can be dichotomized into low FRS (FRS >20) or high FRS (FRS ≥ 20 or confirmed 
CAD) categories. 
Vascular Progenitor Cells 
Emerging evidence suggests that vascular progenitor cell (VPC) populations are a 
sensitive indicator of cardiovascular health. VPCs are circulating progenitor cells with 
angiogenic properties 
23, 24
. They have been referenced in the literature under many 
names, including circulating angiogenic progenitors, peripheral blood mononuclear cells, 
and circulating progenitors from the bone marrow. Much of the research to support their 
role in the vasculature focuses on a subpopulation of VPCs, endothelial progenitor cells 
(EPCs). EPCs are mobilized from the bone marrow into peripheral blood circulation 
through endogenous factors (including cytokines, hormones, and growth factors) and 
exogenous factors (including statin use, exercise, injury, ischemia, and tumors) 
25
. 
Following mobilization, EPCs are found lining the endothelium. The endothelium 
mediates coagulation, vasodilatation, thrombosis and thromboresistance, smooth muscle 
cell proliferation, and muscle wall inflammation. EPCs are necessary for upkeep and 
repair of the endothelium 
26
 by participating in revascularization including angiogenesis 
(new vessel formation from pre-existing vessels) and vasculogenesis (de novo vessel 
formation) 
25
. Decreased EPC levels are associated with endothelial dysfunction, which is 
5 
a hallmark of atherosclerosis development and a key mechanism in myocardial infarction 
27
 . Cigarette smoking, hypertension, hypercholesterolemia, diabetes, obesity, CAD, and 
congestive heart failure are all associated with endothelial dysfunction 
28
. In humans, 
exposure to combustion pollutants is associated with vasoconstriction 
29
. In mice, 
combustion pollutant exposure is associated with decreased endothelial-mediated 
vasodilatation 
29
. Thus, EPC levels are reduced in populations with CVD. EPC levels are 
also reduced in healthy people populations exposed to combustion pollutants 
30
. 
Air Pollution and CVD 
There is growing evidence that air pollution exposure should be considered a 
modifiable risk factor for CVD. In 2004, the American Heart Association issued its first 
scientific statement regarding CVD risk and particulate matter exposure 
31
, and in 2010, 
they issued another scientific statement with a much larger body of work highlighting 
that exposure to fine particulate matter is a modifiable risk factor for CVD 
32
. Air 
pollution has been found to trigger CVD events and increase CVD severity. Associations 
between fine particulate matter, aerosolized particles with an aerodynamic diameter of 
2.5 µm or less (PM2.5), and CVD have been defined both spatially and temporally. A 10 
μg/m3 increase in PM2.5 concentration has been associated with a 4.5% increased risk of 
ischemic heart disease events in short term exposure 33. An interquartile range increase in 
PM2.5 over long term exposure has been associated with a 16% increased odds of acute 
myocardial infarction (95% confidence interval (CI): 1.04–1.29) 34. Exposure to traffic-
generated air pollution has been associated with an odds ratio of 2.92 (95% CI: 2.22–
3.83) for a nonfatal myocardial infarction 
35
 and 2.54 (95% CI: 1.96–3.29) for myocardial 
infarction mortality 
36
. People living closer to a major roadway or highway, a common 
6 
measure used to indicate traffic exposure, have been reported to be at higher risk for 
CAD mortality (relative risk 1.29, 95% CI: 1.18–1.41) 37. Living closer to a road has also 
been associated with increased cardiovascular mortality following a myocardial 
infarction, suggesting that people who have experienced a cardiovascular event may be 
more susceptible 
38
. Compared with people living 200m or more from a major roadway, 
odds ratios for coronary artery calcification were 1.63 (95% CI: 1.14–2.33) for 
individuals living 50m or less from a major roadway and 1.34 (95% CI: 1.00–1.79) for 
individuals living between 50m and 100m from a major roadway 
39
. This suggests an 
association between roadway traffic exposure and vascular outcomes. 
Mechanisms of PM2.5 Toxicity 
It is well-understood that PM2.5 can be inhaled and adversely affects the 
respiratory system, but research indicates that it also affects the vascular and 
cardiovascular systems. There are three biological pathways by which PM2.5 exposure 
may contribute to heart disease. First, the presence of PM2.5 in the lung bronchioles elicits 
pulmonary oxidative stress and inflammation. This results in increased cellular 
inflammatory responses including: increased cytokine levels; increased activation of 
white blood cells and platelets; increased inflammatory markers (C-reactive protein 
(CRP)); and increased thrombosis factors (fibrinogen). Ultimately this systemic oxidative 
stress and inflammation leads to endothelial cell dysfunction (functional impairment of 
the cells that line blood vessels), vasoconstriction (constriction of the blood vessels), and 
progression of atherosclerosis. In the second pathway, the presence of PM2.5 in the 
bronchioles causes activation of the lung autonomic nervous system (ANS) reflex arcs. 
This causes an imbalance in the ANS where the sympathetic nervous system (SNS; fight-
7 
or-flight response) response is increased, and the parasympathetic nervous system 
(PSNS; resting state) response is inhibited. Outcomes include increases in 
vasoconstriction, blood pressure, platelet aggregation, heart rate, endothelial dysfunction 
(an imbalance between vasoconstriction and vasodilation), and systemic oxidative stress 
and inflammation. In the final pathway, PM2.5 in the bronchioles may lead to 
translocation of PM2.5 or its constituents (ultrafine particulates, soluble metals, or organic 
compounds) into circulating blood. This may cause vasoconstriction, endothelial 
dysfunction, increased blood pressure, and systemic oxidative stress and inflammation. 
Each of these three pathways suggest that the cardiovascular effects of particulate matter 
exposure may be mediated by vascular effects of environmental exposures 
31, 32, 40, 41 , 42. 
Acrolein 
Acrolein (2-propenal) is a combustion air pollutant associated with tobacco 
smoke, vehicular exhaust, open fires, and industrial emissions. Acrolein is a highly 
reactive electrophilic compound found in air, soil, and water, but it rapidly evaporates 
from soil and water, with a half-life in the environment of approximately 1 day 
43
. People 
are also exposed to acrolein through foods, including beer, cheese, bread, and fried food 
44
, and acrolein is formed endogenously through biochemical processes of lipid 
peroxidation. Targets for acrolein toxicity include the hematological, ocular, respiratory, 
and cardiovascular systems 
43
. Acrolein metabolism in the body results in the formation 
of 15 detectable products. About 20–30% of acrolein is excreted through feces (none of 
the individual metabolites are excreted through the feces in significant quantities), while 
60–70% of acrolein is excreted through urine 45. Hydroxypropylmercapturic acid 
(HPMA) is the acrolein metabolite found in highest quantity in the urine and is only 
8 
produced by acrolein metabolism 
46
. Acrolein undergoes conjugation with glutathione, 
cleavage of the γ-glutamic acid and glycine residues, n-acetylation of the cysteine to form 
S-(3-oxyproply)-N-acetylcysteine (OPMA), and reduction of OPMA to form HPMA 
47
. 
Acrolein poses a high risk for cardiovascular toxicity. Acrolein exposure is 
associated with increased CVD risk, including hypertension, atherogenesis, decreased 
plaque stability, suppression of cardiac flow, thrombosis, and cardiac contractility 
48
. 
Acrolein exposure in mice is associated with dyslipidemia, decreased VPC levels, and 
endothelial dysfunction 
49-51
. Additionally, protein-acrolein adducts have been found in 
atherosclerotic lesions in the vessels of mice exposed to acrolein 
51
. In human endothelial 
cells, acrolein can form protein adducts and oxidize thioredoxins, which promotes 
atherogenesis 
48
, but its effects on human VPCs are unknown.  
In addition to being a source of acrolein exposure, cigarette smoking increases 
risk of hypertension and atherosclerosis. Moreover, chronic smoke exposure is associated 
with decreased EPC levels 
52
. It is predicted that 50–70ppm of acrolein is generated in 
tobacco smoke, compared to 6–8ppm generated by automobile exhaust from gasoline and 
diesel engines 
51, 53
. Smoke exposure can be empirically measured by determining 
metabolite levels. Nicotine, a metabolite of tobacco smoke, has a shorter in vivo half-life 
than cotinine, a nicotine metabolite, with an in vivo half-life of 2–3 hours for nicotine in 
blood, compared to 15–19 hours for cotinine 54. Cotinine can be measured in urine, 
saliva, and serum for acute exposures, and can be measured in hair to assess chronic 
exposure. Cotinine is detectable in the system for up to 7 days.  
9 
Summary 
The current study addresses an important problem: CVD is the primary cause of 
morbidity and mortality and is associated with high economic burden. This research 
investigates how environmental exposures may contribute to CVD risk. The results of 
this investigation will expand scientific knowledge by exploring the association of VPCs 
with CVD and acrolein’s primary metabolite. Theoretically, this association could 
become an example and guide for future understanding of CVD risk consequences in 
combustion pollutant exposure. Understanding the association between acrolein exposure 
and CVD susceptibility will be important for future CVD prevention intervention policies 
and mitigation of environmental risks, which may ultimately reduce the environmental 
burden associated with CVD.   
The current study investigates the association between environmental pollution 
exposure and VPC levels. Chapter 1 presents an investigation of the relationship between 
circulating VPC counts and CVD risk. Chapter 2 examines the relationship between 
circulating VPC counts and HPMA, an acrolein metabolite. Chapter 3 explores the 
relationship between circulating VPC counts and residential proximity to roadways. 
Results of this investigation build support for the association between VPCs and CVD 
risk and environmental exposures. The scientific knowledge attained by defining these 
associations has the potential to drive future mechanistic pathway explorations, impact 
pollution prevention interventions, and guide therapeutic interventions in the field of 
environmental cardiology. 
  
10 
OVERALL METHODS 
The following is a listing of methods common to each chapter. Methods that are 
specific to each chapter are included in the methods section of the respective chapter. 
Please note that the populations are slightly different in each chapter depending on the 
outcome variable measures and missing data.  
Study Population 
To test the research hypothesis, 240 adults undergoing primary or secondary 
preventive treatment for CVD at the University of Louisville Hospital and/or Clinic 
System were recruited between October 2009 and March 2011. All study consent forms 
and research protocols were approved through the Institutional Review Board at the 
University of Louisville (IRB 09.0174). 
 Inclusion criteria: Eligible individuals were (1) 18 years of age or older at the 
time of enrollment; and  (2) patients of the University of Louisville Hospital and/or Clinic 
System requiring primary or secondary prevention for cardiovascular disease (see the 
Case Definition section below).  
Exclusion criteria: (1) Persons unwilling or unable to provide informed consent; 
(2) subjects with significant and/or severe co-morbidities including the following 
conditions: significant chronic lung, liver, kidney, hematological, or neoplastic disease; 
chronic neurological or psychiatric illness; chronic infectious disease such as HIV or 
hepatitis; severe coagulopathies; drug/substance abuse; and chronic cachexia; (3) 
11 
pregnant women; and (4) prisoners and other vulnerable populations were excluded from 
the current study.  
Patients who met the enrollment criteria answered a brief questionnaire to obtain 
demographic information, address, CVD history, tobacco smoke exposure, alcohol 
intake, physical activity, and baseline clinical characteristics. 
Case Definition 
Primary prevention. In the current study, primary prevention cases were defined 
as individuals with heart disease risk factors, including hypertension, 
hypercholesterolemia, obesity, and diabetes that require management, but who had no 
evident coronary artery disease (CAD). Therefore, primary prevention patients had 
cardiac risk factors, but no CAD. 
Secondary prevention. Secondary prevention cases were defined as individuals 
with heart disease risk factors that required management/treatment and had evident heart 
disease. That is, secondary prevention patients had a clinical manifestation of CAD and 
were undergoing modification of risk factors. As such, in the current study, the absence 
or presence of CAD determined whether a patient was defined as primary or secondary.  
Questionnaire 
All participants in the study were administered an interview questionnaire to 
determine their medical and familial history of CVD. The questionnaire, which was 
created by a cardiologist, was descriptive and asked questions regarding their 
demographic information; residential address; smoking status and history; secondhand 
smoke exposure; alcohol consumption; physical activity status; medication usage; and 
CVD history including heart attack, heart failure, angina; hypertension, 
12 
hypercholesterolemia, diabetes, stroke, revascularization, arrhythmia, peripheral artery 
disease, aortic aneurism, and bleeding disorders. Medical records were reviewed to verify 
addresses, medication history, and to provide the blood pressure reading at the time of 
visit.  
Risk Factor Definitions 
Patients were asked if they had been told by a doctor that they had CVD risk 
factors or conditions. Hypertension was defined as systolic blood pressure ≥ 140 mmHg 
or diastolic blood pressure ≥ 90 mmHg. Diabetes mellitus includes glycosylated 
hemoglobin test (hbA1C) results ≥ 6.5%, fasting plasma glucose levels  ≥ 126 mg/dL, 
and/or oral glucose tolerance test blood glucose levels ≥ 200 mg/dL. Hyperlipidemia was 
defined as having total cholesterol of  240 mg/dL or above, high-density lipoprotein 
(HDL) levels less than 40 mg/dL for men or less than 50 mg/dL for women, low-density 
lipoprotein of 160 mg/dL or greater, and/or triglyceride levels of 200 mg/dL or more.
1
 
Biological Sample Collection and Processing 
Biological samples (urine, blood) were obtained from each participant. Urine 
collected at the time of the visit was used to measure the levels of urine acrolein and 
nicotine metabolites. Blood sampling was performed by a licensed phlebotomist or nurse 
by venipuncture. Approximately 8 mL of blood was collected in a Vacutainer® CPT 
Mononuclear Cell Preparation Tube (Becton Dickinson) for VPC analysis, 2.6 mL in a 
Vacutainer® ACD tube for platelet mononuclear cell aggregate analysis, 6 mL in a 
Vacutainer® Serum Tube for high-sensitivity C-reactive protein analysis, and 6 mL in a 
Vacutainer® K2 EDTA (plasma) Tube for fibrinogen analysis. 
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VPC Quantification 
Human VPCs were identified by f -  flow 
cytometry following the methods first described by Duda et al. 
55
 and modified by 
O’Toole et al. 30. Within 24 hours of the blood draw, blood was separated in the CPT 
mononuclear separator tube by centrifugation at 2750 rpm for 30 minutes. Mononuclear 
cells were separated from serum by centrifugation at 1500 rpm for 10 min. The pelleted 
cells were then washed twice with 2% FBS in PBS and then incubated with 2%FBS/PBS 
and FcR Blocking Reagent (Miltenyi Biotec) for 10 minutes. on ice in the dark. The cells 
were incubated in the dark for 30 minutes. on ice with a panel of fluorescently-
conjugated antibodies including:  PE-labeled anti-CD34 (Becton Dickinson), APC-
labeled anti-AC133 (Miltenyi Biotec), PE-Cy5.5-labeled anti-CD14 (Abcam), APC-
AlexaFluor 750-labeled anti-CD45 (Invitrogen), PE-Cy7-labeled anti-CD16 (Becton 
Dickinson), FITC-labeled anti-CD31 (Becton Dickinson), anti-CD41a (Becton 
Dickinson) and anti-CD235a (Becton Dickinson), Pacific Blue (Pacific Blue monoclonal 
antibody labeling kit; Invitrogen), and a marker for dead cells (LIVE/DEAD fixable dead 
cell stain; Invitrogen). The cells were then pelleted and washed once in 2%FBS/PBS. 
Finally, the cells were resuspended in 1% FACS formaldehyde 
30
. 
Following cell resuspension, 500,000 events were collected using the LSR II flow 
cytometer (Becton Dickinson). Positive/negative boundaries for all gating was 
accomplished using unstained controls. The lymphocyte population was selected in the 
initial gating scheme by measuring the population that was negative for CD235a, CD41a, 
and the dead cell marker (all stained with pacific blue). From that population, the CD14 
and CD16 negative population were selected. Cells positive for both CD34
+
 (stem cells) 
14 
and CD31
+
 (endothelial cells) were selected for the final population. Additionally, VPCs 
were subdivided into monocytic/non-monocytic (CD45
+/dim
) and early/mature progenitors 
(AC133
+/–
). FlowJo software was used to analyze the collected events. VPC counts were 
normalized to the sample volume used in analysis 
30
. The gating scheme is shown in 
Figure 1. 
Platelet Mononuclear Cell Aggregate Identification 
Peripheral blood was collected in an ACD tube. One mL of blood was fixed with 
1.3 mL of 4% paraformaldehyde and diluted with 3 mL of deionized water for a 
minimum of 30 minutes. on ice. Red blood cells were lysed with the addition of 24 mL of 
water. The sample was centrifuged for 10 minutes. at 400g, and the pelleted cells were 
resuspended with 1 mL of Tyrode’s buffer. The Tyrode’s-resuspended cells were divided 
into 2 equal aliquots. Both aliquots were incubated on ice with FcR Blocking Reagent 
(Miltenyi Biotec) for 5 minutes. The first aliquot of the platelet-mononuclear cells was 
then incubated with the following antibodies for 30 minutes. on ice: FITC-labeled anti 
CD41a (Becton Dickinson) and PerCP-Cy5.5-labeled anti-CD45 (Becton Dickinson). 
The second aliquot was labeled with isotype control antibodies and incubated on ice for 
30 minutes. Following incubation, both aliquots were washed and resuspended in 
Tyrode’s Buffer. Using FACS flow cytometry, platelet mononuclear cell aggregates were 
counted as events that were labeled FITC (CD41
+
) and PerCP-CY5.5 (CD45
+
) and were 
calculated as a percentage of total events 
30
. 
Cotinine Quantification 
Cotinine was measured in urine using gas chromatography / mass spectrometry 
(GC/MS) following the methods described by Man et al. Urine in quantities of 1 mL for 
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self-reported current non-smokers or 0.25 mL for self-reported current smokers (diluted 
with 0.75 mL of deionized water) was pipetted into Teflon vials. Either 0.2 nmoles (non-
smokers) or 0.5 nmoles (smokers) of the internal standard of D-3 cotinine in 0.175 mL of 
methanol was added. This was followed by the addition of 0.05 mL of 0.1M NaOH and 
0.325 mL of chloroform. This mixture was vortexed for 1 min. and then centrifuged at 
13000 rpm for 4 minutes. After discarding the aqueous layer, 100 mg of sodium sulphate 
was added to remove any excess water, briefly mixed, and the solution was allowed to sit 
at room temperature for 1 minute. The clear organic extract was transferred to a gas 
chromatography vial and 0.001 mL was injected to the gas chromatographer. Ions used to 
monitor cotinine were 176 (cotinine) and 179 (D-3 cotinine) 
56
.  
High Sensitivity C-Reactive Protein Quantification 
The quantitative measurement of high sensitivity C-reactive protein (hsCRP) in 
serum is performed using the VITROS Chemistry Products hsCRP Reagent in 
conjunction with the VITROS Chemistry Products Calibrator Kit 17 and VITROS 
Chemistry Products FS Calibrator 1 on VITROS 5,1 FS Chemistry Systems. Samples, 
calibrators, and controls are mixed with Reagent 1 containing a buffer. Addition of anti-
CRP antibodies coupled to latex microparticles (Reagent 2) produces an 
immunochemical reaction yielding CRP antigen/antibody complexes. The turbidity is 
measured spectrophotometrically at 660 nm. Once a calibration has been performed for 
each reagent lot, the CRP concentration in each unknown sample can be determined 
using the stored calibration curve and the measured absorbance obtained in the assay of 
the sample. Values from hsCRP were divided into three groups for low (< 1.0 mg/L), 
intermediate (1.0-2.9 mg/L), and high (≥3 mg/L) levels 57. 
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Fibrinogen Quantification 
The STA Fibrinogen kit is intended for the quantitative determination of 
fibrinogen in plasma by the Clauss clotting method 
58
. In the presence of excess 
thrombin, the clotting time of diluted plasma is inversely proportional to the level of 
plasma fibrinogen. The clot is detected by the STA-Compact, a fully automated 
coagulation instrument that uses an electromagnetic mechanical clot detection system. 
The oscillation of a steel ball within the cuvette containing thrombin and diluted plasma 
is monitored by the STA-Compact. When the oscillation of the steel ball is stopped by 
clot formation, the sensor registers the time in seconds. The time is read from a stored 
curve on the STA-Compact. The time read is translated into a fibrinogen concentration 
based on the manufacturer’s standard curve from the STA-Compact. 
Socioeconomic Status Determination 
To determine socioeconomic status (SES), addresses were geocoded in 
Geographic Information System (GIS) ArcMap 9.3 (ESRI, Redlands, CA). Data for 
geocoding addresses was provided by the Louisville/Jefferson County Information 
Consortium (LOJIC) composite locator in ArcGIS. SES was estimated using the proxy 
variable, “median household income,” and was provided at the block group level from 
the 2000 U.S. Census. 
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Figures and Tables 
 
Figure 1. Flow cytometry gating scheme for VPC populations. 
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CHAPTER I: 
Circulating Vascular Progenitor Cells are Associated with Cardiovascular Disease 
Risk 
Introduction 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
worldwide 
1
. Understanding CVD risk is critical to characterizing and enhancing future 
preventive approaches. Vascular progenitor cells (VPCs) are believed to be necessary for 
upkeep and repair of blood vessels 
26
 by participating in revascularization, including 
angiogenesis 
23
 and vasculogenesis 
59-61
. Reduced migratory capacity and quantity of 
VPCs are associated with endothelial dysfunction 
62
, which is a hallmark of 
atherosclerosis development 
63
. VPC levels have been shown to be inversely associated 
with intima-media thickness, also linked with atherosclerosis 
64
. Cigarette smoking, 
hypertension, hypercholesterolemia, diabetes, obesity, coronary artery disease (CAD), 
and congestive heart failure are all associated with endothelial dysfunction 
28
. VPC 
counts are positively associated with brachial reactivity 
65, 66
. Circulating VPC levels have 
been suggested to reflect CVD risk, with inverse associations between VPC levels and 
traditional CVD risk factors including smoking
52
, diabetes mellitus
67
, total cholesterol
65, 
68
, and low-density lipoprotein (LDL) cholesterol 
63, 68
. They have also been inversely 
associated with the Framingham Risk Score (FRS) 
65
 
69, 70
. VPCs are often depleted in 
populations with CVD 
63, 65, 69
, increased CVD severity 
66, 71-73
, and CVD mortality 
74
. 
The aforementioned results have not been entirely consistent in that a number of other 
19 
studies have observed positive associations with VPC levels and the FRS 
64
, smoking 
66
, 
and found no VPC differences in hypertension, hyperlipidemia, and diabetes 
74
. 
Discrepancies in these findings are likely because VPCs are a heterogeneous population 
containing cells with different angiogenic potential, and it has not yet been determined 
which specific cell types are associated with CVD risk and specific CVD risk factors. We 
investigated the relationship between VPCs and CVD risk factors using antigenically-
defined VPC sub-populations with demonstrated angiogenic potential (through inhibitor 
of DNA binding 1 (Id1) positive staining). Our study determined which among the 15 
VPC populations, were associated with varying degrees of CVD risk in an at-risk 
population.  
A 7-color flow cytometry procedure was used to describe the VPC profile from 
peripheral blood cells among a population with varied degrees of CVD risk. The use of 
antigenic markers CD31
+
 (endothelial), CD34
+
 (stem), CD45
+/dim
 (hematopoietic/ non-
hematopoietic), and AC133
+/–
 (early/ late stem) is novel because previous studies have 
used different antigenic markers to define VPCs, some of which were not specific to 
VPCs including, 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate 
labeled acetylated low-density lipoprotein (DiI-Ac-LDL) and lectin. Previous human 
studies have also assessed cells after growth in culture, a measure indicating cellular 
growth capacity and function – rather than the number of cells in circulation. This has 
resulted in mixed findings in terms of the association between VPCs and CVD risk 
factors. 
In summary, several studies have suggested that circulating VPC levels are 
decreased in populations with CVD; however, these studies used cellular definitions that 
20 
were not specific to VPCs. We evaluated the relationship between CVD risk and VPC 
levels using antigentically defined VPCs with demonstrated angiogenic potential. We 
hypothesize that VPC levels are inversely associated with CVD risk. Fifteen VPC 
populations measured from peripheral blood using VPC-specific antigenic markers were 
quantified using flow cytometry. 
Methods 
Study Population 
See Overall Methods (Study Population). 
Case Definition 
See Overall Methods (Case Definition).  
Questionnaire 
See Overall Methods (Questionnaire). 
Biological Sample Collection and Processing 
See Overall Methods (Biological Sample Collection and Processing). 
VPC Quantification 
VPC populations in blood were characterized using a 7-color flow cytometry 
procedure using established markers: CD31
+
, CD34
+
, CD45
+/dim
, and AC133
+
. This 
method was first described by Duda et al. to define circulating endothelial cell (CEC) and 
circulating progenitor cell (CPC) populations in human peripheral blood 
55
. Additionally, 
O’Toole et al. used modifications of this model to determine human VPC populations 
using the aforementioned 4 antigenic markers 
30
. We expanded the number of cell 
populations from 6 to 15 (see Table 1). See Overall Methods (VPC Quantification). 
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Selected VPC populations were also assessed for the transcription factor inhibitor 
of DNA binding 1 (Id1), an antigenic marker for endothelial progenitor cells.  Murine 
studies suggest that this marker indicates endothelial progenitor cell activity; when Id1
+
 
cells are suppressed from the bone marrow in trans-genic mice, angiogenesis is impaired 
in tumors, and circulating endothelial progenitor cell levels in circulation are depleted 
75-
77
. The current study used modifications of the Wheat et al. protocol for Id1 
determination 
51
. White blood cells isolated from human blood of healthy volunteers 
(University of Louisville IRB 11.0432) were sorted for selected subsets by f -
, permeabilized (0.1 % Triton X-100/ phosphate buffered 
saline (PBS), room temperature, 3 minutes), blocked (1 % bovine serum albumin 
(BSA)/PBS, room temperature, 15 minutes) and incubated over night with the primary 
antibody against Id1 (proteintech, Chicago, Il; 1:250) at 4°C. After incubation with the 
fluorescence labeled secondary antibody (1:500, 1 hour, room temperature; anti-rabbit-
488, Invitrogen, Carlsbad, CA), cells were mounted with DAPI containing mounting 
media (Invitrogen, Carlsbad, CA) and images were taken by fluorescence microscopy 
(EVOSfl, AMG, Hill Creek, WA). 
Platelet Mononuclear Cell Aggregate Identification 
Platelet mononuclear cell aggregates were identified using flow cytometry 
following the procedures described in O’Toole et al.  Using flow cytometry, platelet 
mononuclear cell aggregates were counted as events that were FITC (CD41
+
) and PerCP-
CY5.5 (CD45
+
) and were calculated as a percentage of total events 
30
. See Overall 
Methods (Platelet Mononuclear Cell Aggregate Identification). 
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Statistical Analysis 
Influence of CVD Risk on VPCs, Thrombosis and Inflammation 
Independent samples t-tests (Wilcoxon methods when appropriate) were used to 
test for differences (association) in mean VPC values, thrombosis markers (fibrinogen 
and platelet mononuclear cell aggregates), and inflammation markers (hsCRP), between 
those in the low Framingham Risk Score (FRS) category (FRS ≤ 20) and high FRS 
category (FRS ≥ 20 or established CVD). Additionally, t-test techniques were used to 
compare these variables among people with a low number of risk factors (< 2 CVD risk 
factors among age ≥ 40 years, male gender, hypertension, diabetes, hyperlipidemia, 
diabetes, and current smoking) and a higher number of risk factors (≥ 2 CVD risk 
factors). This more crude comparison was utilized to determine if individuals with a 
small number of risk factors in the study population were different from the remaining 
population or if the use of this crude variable provided additional information or 
understanding in addition to the FRS t-test comparisons. The VPC levels assessed were 
log transformed for normality, consistent with previous literature 
74
. VPC values 
presented are the VPC counts normalized to sample volume for consistency. 
Additionally, population demographics and CVD risk factors were compared 
among tertiles of low, medium, and high log-transformed VPC levels for a VPC 
population positively associated with the FRS category and a population inversely 
associated with the FRS category. Tertiles were defined by dividing the population’s 
VPC levels into cut points for 3 evenly distributed groups. Demographics and CVD risk 
factors were compared using χ-squared analysis for categorical variables and analysis of 
variance (ANOVA) for continuous variables. 
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Simple linear regression modeling techniques were used to test for associations 
between VPC and the FRS category (unadjusted). Generalized Linear Modeling (GLM) 
techniques examined whether FRS category was independently associated with VPC 
levels, adjusting for, ethnicity, whether they consumed alcohol, body mass index (BMI) 
and, socioeconomic status (SES; median household income at the block group level). 
GLM techniques are appropriate for variables that are not normally distributed. The 
VPCs followed a gamma distribution rather than a normal distribution; therefore, the 
GLMs with each VPC entered as the dependent variable utilized the gamma probability 
distribution and the log link function. Traditional model fit statistics (log-likelihood) were 
used to develop the most parsimonious model. In addition we tested whether higher order 
modeling (e.g., exponential, cubic) improved model fit using traditional model-fit 
statistics (AIC, log-likelihood, etc.).  
Influence of Thrombosis and Inflammation on VPCs 
Similar to above, simple linear regression modeling techniques were used to test 
for associations between (1) VPC and thrombosis markers (fibrinogen and platelet 
mononuclear cell aggregates) and (2) VPC and inflammation markers (hsCRP) 
unadjusted. That is, we tested whether VPC values were associated with thrombosis 
markers and/or inflammation markers, unadjusted. Also similar to above, GLM 
techniques for the VPC models utilized the gamma probability distribution and the log 
link function to examine whether thrombosis (fibrinogen and platelet mononuclear cell 
aggregates), and inflammation markers (hsCRP) were independently associated with 
VPC levels, adjusting for hypertension, hyperlipidemia, diabetes, smoking, age, ethnicity, 
alcohol, gender, BMI, and SES. Traditional model fit statistics (log-likelihood) were used 
24 
to develop the most parsimonious model. In addition we tested whether higher order 
modeling (e.g., exponential, cubic) improved model fit using traditional model-fit 
statistics (AIC, log-likelihood, etc.). 
Note: The current study only reports/presents the models that had a significant 
relationship with a VPC and the main effect of interest. Also, there was significant 
overlap between many of the 15 VPC populations measured; therefore associations for 
each VPC population were measured separately in individual GLMs.  
Results 
Participant Characteristics 
The Healthy Heart Study population was 51±10 years of age; 53.6% (n=53.6) 
male; 56.3% (n=103) Caucasian; 40.3% (n=73) current smokers; 82.2% (n=148) 
hypertensive; 64.8% (n=116) had hypercholesterolemia; 59.6% (n=106) obese; and were 
taking medications including 55.3% (n=99) angiotensin-converting-enzyme (ACE) 
inhibitors, 63.7% (n=114) beta-blockers, and 52.5% (n=94) statins. Population 
demographics are shown in Tables 3 and 4. Small differences between the demographics 
are due to missing data attributed to log transforming VPC-levels: 0 values cannot be log 
transformed and are, therefore, missing. 
Id1 Staining 
Id1 staining was used to determine if the isolated VPC populations were 
endothelial progenitor cells. VPC-1 (CD31
+
/34
+
/45
dim
), VPC-2 (CD31
+
/34
+
/45
+
), VPC-5 
(CD31
+
/AC133
+
), VPC-6 (CD31
+
/34
+
), VPC-7 (CD31
+
/34
+
/45
dim
/AC133
–
), VPC-8 
(CD31
+
/34
+
/45
+
/AC133
–
), VPC-11 (AC133
+
), and VPC-13 (CD34
+
/AC133
+
) were 
positive for Id1 (Figure 2). VPC-4 (CD31
+
/34
+
/45
+
/AC133
+
) and VPC-14 
25 
(CD34
+
/45
+
/AC133
+
) had positive and negative Id1 cells (Figure 2). Id1 staining on the 
remaining cell populations is pending. 
CVD Risk and its association with VPCs, Thrombosis, and Inflammation 
Comparisons between VPC levels, thrombosis, and inflammation were made 
among the risk score levels. A number of the VPC populations and fibrinogen were 
significantly different between the low and high FRS populations, Table 2. Specifically, 
the high FRS population had significantly higher levels of VPC-1 (CD31+/34+/45dim; 
p=0.023), VPC-3 (CD31
+
/34
+
/45
dim
/AC133
+
; p=0.008), VPC-13 (CD34
+
/AC133
+
; 
p=0.020), VPC-15 (CD34
+
/45
dim
/AC133
+
; p=0.006), and fibrinogen (p=0.006).  
Additionally, comparisons between VPC levels, thrombosis, and inflammation 
were also made among the number of risk factors, Table 3. The high risk population had 
≥ 2 CVD risk factors and the low risk population had < 2 CVD risk factors. None of the 
VPCs, hsCRP, or fibrinogen were different between the risk factor strata, but platelet 
mononuclear cell aggregates were higher in the high-risk population (p=0.040).  
Demographic Comparisons among VPC-3 Tertiles 
Differences between the characteristics of the populations within low, medium, 
and high VPC-3 (CD31
+
/34
+
/45
dim
/AC133
+
) tertiles are shown in Table 4. VPC-3 was 
selected because it is the most specific sub-population positively associated with FRS. 
Participants in the high FRS category (FRS ≥ 20 or experienced a cardiovascular event) 
were significantly more likely to have high VPC-3 levels (p=0.004). Lymphocyte count 
was positively associated with VPC-3 levels (p<0.001). Fibrinogen was positively 
associated with VPC-3 levels (p=0.003). 
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Demographic Comparisons among VPC-5 Tertiles 
Differences between the characteristics of the populations within low, medium, 
and high VPC-5 (CD31
+
/AC133
+
) tertiles are shown in Table 5. VPC-5 was selected 
because it is positively (not significant) associated with FRS in the t-test comparison; 
levels in the high-FRS were more than double in the low-FRS population. Only 
lymphocyte count was positively associated with VPC-5 levels (p<0.001). 
Adjusted Association between FRS and Circulating VPC Levels 
Significant associations between FRS category and VPC levels adjusted for 
ethnicity, alcohol, body mass index (BMI), and socioeconomic status (SES; median 
household income at the block group level) are shown in Table 6. FRS category was 
inversely associated with VPC-5 (CD31
+
/AC133
+
; β=-0.679, p=0.003). FRS category 
was positively associated with VPC-3 (CD31
+
/34
+
/45
dim
/AC133
+
; β=0.840, p<0.001), 
VPC-13 (CD34
+
/AC133
+
; β=0.706, p=0.001), and VPC-15 (CD34+/45dim/AC133+; 
β=0.864, p<0.001). None of the remaining covariates explored above improved model fit 
and are not included in the final model. 
Adjusted Associations between Thrombosis and VPC Levels 
The association between VPCs and thrombosis was assessed using fibrinogen as a 
marker of thrombosis (Figure 3A). The regression model adjusted for hypertension, 
hyperlipidemia, diabetes, smoking, age, ethnicity, alcohol, gender, BMI, and SES (Figure 
3A).  VPC-1 (CD31
+
/34
+
/45
dim; β=0.002, p=0.007), VPC-3 (β=0.002, p=0.004), VPC-13 
(β=0.002, p=0.004), and VPC-15 (β=0.003, p=0.003) were positively associated with 
fibrinogen. In addition, as seen in Figure 3B, C, D, and E, positive associations are 
demonstrated in scatterplots of fibrinogen and the predicted means of the VPCs from the 
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adjusted regression models for VPC-1 (R
2
= 0.399, p<0.001), VPC-3 (R
2
= 0.335, 
p<0.001), VPC-13 (R
2
= 0.386, p<0.001), and VPC-15 (R
2
= 0.414, p<0.001). 
The association between VPCs and thrombosis was also assessed using platelet 
mononuclear cell aggregates as a marker of thrombosis. As seen in Figure 4A, there was 
a positive association between VPC-6 (CD31
+
/34
+
; β= 0.040, p=0.036), VPC-9 (CD34+; 
β= 0.044, p=0.026), and VPC-14 (CD34+/45+/AC133+; β= 0.118, p<0.001) and platelet 
mononuclear cell aggregates (CD41
+
/45
+
) adjusted for hypertension, hyperlipidemia, 
diabetes, smoking, age, ethnicity, alcohol, gender, BMI, and SES. In addition, as seen in 
Figure 4B, C, and D, positive associations are demonstrated in scatterplots of platelet 
mononuclear cell aggregates and the predicted means of the VPCs from the adjusted 
regression models for VPC-6 (R
2
= 0.287, p<0.001), VPC-9 (R
2
= 0.315, p<0.001), and 
VPC-14 (R
2
= 0.431, p<0.001). 
Adjusted Association between Inflammation and VPC Levels 
 The association between VPCs and inflammation was assessed using hsCRP 
levels as a marker of inflammation (Figure 5). The adjusted regression excluded the 
population with hsCRP levels above 10 mg/L (n=19) due to increased likelihood of an 
infection or inflammatory diseases unrelated to cardiovascular disease 78, 79. The models 
were adjusted for hypertension, hyperlipidemia, diabetes, smoking, ethnicity, alcohol, 
gender, BMI, and SES. VPC-5 (CD31
+
/AC133
+
) and VPC-11 (AC133
+
) levels were 
significantly inversely associated with hsCRP levels (β= -0.076, p= 0.042) and (β= -
0.078, p= 0.037). In addition, as seen in Figure 5B inverse associations are demonstrated 
in a scatterplot of hsCRP and the predicted means of the VPCs from the adjusted 
regression models for VPC-5 (R
2
= 0.032, p=0.033). The scatterplot of hsCRP and the 
28 
predicted means of the VPCs from the adjusted regression models for VPC-11 (R
2
= 
0.008, p=0.278) was not significant. 
Discussion 
We conducted a cross-sectional assessment of the association between VPC levels 
and CVD risk in the Healthy Heart Study. A majority of the VPC populations assessed 
were Id1
+
, indicating they have endothelial progenitor cell lineage. The high FRS 
population had significantly higher levels of VPC-1 (CD31+/34+/45dim), VPC-3 
(CD31
+
/34
+
/45
dim
/AC133
+
), VPC-13 (CD34
+
/AC133
+
), VPC-15 (CD34
+
/45
dim
/AC133
+
), 
and fibrinogen. In the adjusted analysis of VPCs vs. CVD risk, we found that VPC-5 
(CD31
+
/AC133
+
) was significantly inversely associated with the FRS category, while 
VPC-3, VPC-13, and VPC-15 were positively associated with the FRS category. VPC-1, 
VPC-3, VPC-13, and VPC-15 were positively associated with fibrinogen, and VPC-6, 
VPC-9, and VPC-14 were positively associated with platelet mononuclear cell 
aggregates. VPC-5, and VPC-11 (AC133
+
) were inversely associated with hsCRP, which 
is associated with inflammation. 
VPC levels are hypothesized to decrease as CVD risk increases and 
atherosclerosis progresses 
80
. Multiple studies have reported an inverse association 
between the number of risk factors and VPC levels 
63,
 
81
. Vasa et al. found this 
association in CD34
+
/KDR
+
 cells (kinase insert domain receptor (KDR); marks for 
endothelial cells) 63, and Schmidt-Lucke et al. found this association the VPC population  
KDR
+
/CD34
+
/CD45
dim
 
81
. We did not find a significant association between VPCs and 
the number of risk factors. It may be that our population was a rather unhealthy 
population, in terms of cardiovascular health, and there are not enough people with few 
29 
risk factors to accurately depict the association between VPCs and the number of CVD 
risk factors. Future studies should include a comparison population with less than 2 
Framingham risk factors.  
FRS has been associated with decreased VPC levels in other investigations 
65,
 
69, 
70
. In the current study, VPC-5 significantly decreased as FRS category increased. This 
suggests that the depletion of CD31
+
/AC133
+
 may be driving the inverse association with 
FRS and VPC levels. Additionally, these cells were significantly associated with hsCRP, 
suggesting that the association between VPC-5 and FRS may be associated with 
inflammation. Furthermore, VPC-11 (AC133
+
) was inversely associated with FRS 
category in the univariate analysis (not in the adjusted model; β=-0.406, p=0.076); but 
this population was also inversely associated with hsCRP, suggesting reason to 
investigate the potential role of inflammation in depletion of VPCs in the high FRS 
category. More research is required to understand how risk factors potentially influence 
the VPC levels, thereby contributing to risk: more specifically CVD risk factors, e.g. 
hypertension, in the reduction of circulating levels of CD31
+
/AC133
+
 VPCs. A future 
direction for our research involves understanding how each risk factor influences VPC 
levels and incorporating a weight for each into our model. Other future directions should 
involve the prognostic diagnostic utility of VPCs, particularly VPC-5, in the clinical 
setting. 
The current study also determined that 3 cell populations were positively 
associated with the FRS category, VPC-3, VPC-13, and VPC-15. VPC-3 is a sub-
category of VPC-13 and VPC-15, suggesting that VPC-3 may be driving the associations 
seen through the CD31
+
 (endothelial) and CD45
dim 
(non-hematopoietic) phenotypes. 
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Faidini et al. described that as atherosclerosis progresses to an event in low risk 
populations, VPCs are mobilized into circulation 
80
. This suggests that people who have 
had a CVD event may have higher levels of some VPCs. Because the secondary 
preventive population is included in the high FRS category, a cardiovascular event in 
these individuals may have mobilized VPC-3, VPC-13, and VPC-15 into circulation. 
Güven et al. reported a positive association between VPCs and coronary artery disease 
severity 
72
. Shintani et al. demonstrated that VPCs increase following an acute 
myocardial infarction (AMI), with  a peak 7 days post-AMI 
82
. Leone et al. and Massa et 
al. observed that VPC counts increase following an acute AMI by comparison to healthy 
controls 
83, 84
. Similarly, Sobrino et al. and Yip et al. demonstrated increased VPC levels 
following a stroke 
85, 86
. Xiao et al. also indicated a positive association between FRS and 
VPC levels 
64
. Their investigation, however, evaluated a population with FRS ≤ 10, a low 
risk population. Our population included high-risk individuals and secondary preventive 
patients. Additionally, Xiao et al. investigated this association in DiI-Ac-LDL
+
/ lectin
+
 
cells grown in culture, which are markers that are not highly specific to VPCs. 
Furthermore, the culture assay reflects VPC growth and proliferative capacity, rather than 
circulating VPC levels. A second possible explanation for the positive association 
between VPCs and FRS is that as risk increases, the more likely the subjects are receiving 
primary preventive treatment for CVD risk factors. Therefore, they are more likely to be 
taking medications, including statins, which may increase VPC levels 
64, 81, 87, 88
 and VPC 
mobilization 
89-91
. VPC-3, VPC-13, and VPC-15, however, were not associated with 
statin use in the current study population. VPC-3, VPC-13, and VPC-15 were positively 
associated with aspirin use, indicating that aspirin may play a role in the association. 
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When the regression model was adjusted for aspirin, the association between FRS and 
VPC-3, VPC-13, and VPC-15 remained positive and significant. Additionally, these cells 
were positively associated with fibrinogen. This suggests that thrombosis may be driving 
the positive association between FRS and VPC-3, VPC-13, and VPC-15. Moreover, 
fibrinogen was significantly higher in people in the high FRS category (β=51.24, 
p<0.001; adjusted for ethnicity, alcohol, BMI, and SES). Aspirin was positively 
correlated with hypertension and hyperlipidemia in the current study, suggesting that 
future research should assess hypertension and hyperlipidemia in association with VPC-
3, VPC-13, and VPC-15 levels, although there was no association revealed from the 
current at-risk study population. Future directions should investigate risk factors and 
medications that are positively associated with VPCs and the potential for positive 
cardiovascular outcomes. 
There were 2 remaining VPC populations that were inversely associated with FRS 
category in the univariate analysis, VPC-7 (CD31
+
/34
+
/45
dim
/AC133
–; β=-0.419, 
p=0.036) and VPC-11 (AC133
+; β=-0.609, p<0.001). VPC-7 lost significance when BMI 
was entered into the model, the positive association with BMI seems to suppress the 
relationship between FRS category and the VPC-7. VPC-11 lost significance when 
ethnicity was entered into the model; African Americans had significantly higher levels 
of VPC-11. VPC-2 (CD31
+
/34
+
/45
+
) and VPC-8 (CD31
+
/34
+
/45
+
/AC133
–
) were 
positively associated with FRS in the univariate model, but when ethnicity was entered 
into the model, both lost significance. African Americans had significantly lower levels 
of VPC-2 and VPC-8. We do not report the non-significant models as discussed. While 
BMI, ethnicity, and SES seem to be independently associated with some of the remaining 
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VPCs and may account for the differences observed, FRS category may not account for 
the differences after adjustment for these variables. Future planned manuscripts will 
further explore these relationships. 
We found that VPC-1, VPC-3, VPC-13, and VPC-15 levels were positively 
associated with fibrinogen, suggesting a pro-thrombotic state. This association may be 
driven by the CD31
+
 (endothelial) and CD45
dim 
(non-hematopoietic) phenotypes. 
Additionally, the current study found that VPC-6, VPC-9, and VPC-14 were positively 
associated with platelet mononuclear cell aggregate levels, also suggesting a thrombotic 
state. The association may be driven by the CD45
+
 (hematopoietic) and AC133
+
 (early 
stem) cell phenotypes. The thrombin receptor protease activated receptors-1 (PAR-1) is 
expressed on VPCs, and thrombin may activate the fibrinolytic pathway that balances 
thrombosis by breaking down thrombi 
92, 93
. Additionally, VPCs were shown to be 
recruited to resolving venous thrombi 
94
. This suggests that VPC levels could increase in 
the presence of a thrombus. In the current study, some VPC levels were positively 
associated with fibrinogen and platelet mononuclear cell aggregates, verifying this 
hypothesis. Further research is needed to understand the relationship of VPCs with 
thrombosis in advanced stages of CVD. 
We determined that circulating levels of VPC-5 and VPC-11were inversely 
associated with hsCRP in subjects with a range of CVD risk factors. Because systemic 
inflammation is linked to CVD and vascular injury, this association is biologically 
plausible. Previous investigations of this association have provided mixed results. Studies 
that investigated the effects of hsCRP -treated VPCs in culture also demonstrated VPC 
decreases defined as DiI-Ac-LDL
+
/lectin
+
 cells 
95
 and vascular endothelial growth factor 
33 
receptor-2
+
 (VEGFR-2
+
, also known as KDR
+
) cells 
96
. George et al. determined that DiI-
Ac-LDL
+
/ lectin
+
- colony forming units (CFU) were positively associated with hsCRP 
levels 
86
. As previously mentioned, DiI-Ac-LDL and lectin are not highly specific to 
VPCs, and CFUs are more indicative of the proliferative capacity of the isolated VPCs. 
Additionally, inverse associations between hsCRP and VPCs have been found in 
individuals with diabetes mellitus (a major risk factor for CVD) for CD34
+ 
cells 
97, 98
 and 
CD34
+
/133
+  
cells 
97
. In the current study, we did not find an association between CD34
+
 
(VPC-9) or CD34
+
/AC133
+ 
(VPC-13). Schmidt-Lucke et al. showed that circulating 
VPCs, defined as CD34
+
/KDR
+
 cells, quantified using flow cytometry were not 
significantly associated with hsCRP 
99
. Our study also found no significant association 
between CD31
+
/34
+
 (VPC-6) cells and hsCRP (both KDR
+
 and CD31
+
 cells indicate 
endothelial lineage and the VPC-6 population was Id1 positive, also indicating 
endothelial progenitor cell lineage). Results from the current study suggest that VPC-5 
and VPC-11, likely driven by the more specific sub-population VPC-5 (CD31
+
/AC133
+
), 
decreased with increased markers of inflammation in adults at increased heart disease 
risk. Future research should investigate the role of VPC-5 and inflammation. 
Among the multiple strengths of the current investigation, we had a large 
population with varying degrees and types of CVD risk. Because we were able to 
measure 15 different populations of VPCs, we were able to investigate which antigenic 
markers are associated with CVD risk factors. Through the thorough questionnaire and 
medical records review, we were able to conduct an extensive evaluation of CVD risk 
factors. Additionally, we reduced risk of misclassification and potential confounding in 
self-reported smoking status by measuring cotinine levels, the primary urine metabolite 
34 
of nicotine. Cotinine levels accounted for both smoking and environmental tobacco 
smoke exposure. 
Some of the limitations to the investigation involve the type of study we have 
selected. Cross-sectional studies are limited in their ability to demonstrate causality, but 
are useful to identify associations that can be used to generate hypotheses for future 
cohort studies. Other potential limitations include the time of sample collection. Some of 
the research on VPCs indicates that they demonstrate diurnal variations and should be 
collected at the same point each day 
64
. Additionally, studies on urine metabolites suggest 
that the urine sample should be collected at the first catch or first void. Recruitment 
limitations include the inability to recruit a population that is representative of the 
population that visits the clinics. None of the recruiting personnel fluently spoke 
languages other than English; therefore, some potential participants that did not have a 
translator present were not able to provide consent for the study or participate in the 
interview questionnaire. In addition, based on the recruitment being entirely from 
cardiology clinics, we lack a true population-based sample, we had an at-risk population. 
This poses a limitation in being able to generalize the results to the entire population. 
Also, our study does not account for all population variabilities that may affect VPC 
levels; for example, some studies exclude pre-menopausal women because of the VPC 
fluctuations that result due to menstruation 
100, 101
. Our study did not include a variable 
for cyclic variability due to the menstruation phase of female study participants nor did 
we exclude women from study, although the regression models did adjust for gender. 
Future studies should include a healthy comparison population or healthy age- 
and sex-matched controls. Regressing VPCs against the sum of CVD risk factors will be 
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more robust when including more people that have ≤ 1 CVD risk factor. Future planned 
investigations will explore relationships between VPCs and ethnicities. Our population is 
richly diverse with just over 40% of the population being African American, and 
understanding risks and VPC levels in this population will be of added scientific benefit. 
Additionally, the VPC levels should be assessed in their association with CAD severity 
determined by angiography. The association between VPC levels and cardiac output, 
determined through echocardiography, should also be assessed to understand the 
association between VPC levels and cardiac outcomes.  
In summary, these observations suggest that levels of some VPCs are associated 
with increased CVD risk, a pro-thrombotic state, and inflammation. Previous research has 
indicated mixed results in terms of CVD risk and VPC levels. It appears that this is 
because VPCs are a heterogeneous population containing cells with varied angiogenic 
potential. Additionally, some previous research employed markers that are not specific to 
VPCs and assays not specific to circulating VPC levels. The inverse association between 
VPCs and FRS category appears to be driven by the CD31
+
/AC133
+
 phenotype. The 
positive associations between VPCs and FRS category as well as VPCs and fibrinogen 
appear to be driven by the CD31+/34+/45
dim
/AC133
+
 phenotype. The positive association 
between VPCs and platelet mononuclear cell aggregates appears to be driven by the 
CD34
+
/45
+
/AC133
+
 phenotype. The inverse association between VPCs and hsCRP 
appears to be driven by the CD31
+
/AC133
+
 phenotype. Future direction should assess 
VPC changes in a cohort study following people forward in terms of the interaction 
between VPC levels, risk factors, and disease. Determining the phenotype associated with 
risk could guide future use of VPC phenotypes for diagnostic and therapeutic purposes. 
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Figures and Tables 
 
 
Table 1. Listing of the VPC populations identified.  
n/d: not determined.
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Figure 2. Abundance of Id-1 in populations of human blood progenitor cells. 
(A) Fluorescence images (original magnification 60 x) of human blood CD34
+
/AC133
+
, 
CD34
+
/AC133
–
, and CD34
–
/AC133
–
 cells.  White blood cells were sorted by flow 
cytometry and fluorescence labeled with Alexa-488-Id-1 and DAPI. Phase-contrast and 
fluorescence images (left panel, original magnification 60 x) of human blood sorted for 
CD31
+
/CD34
+
/CD45
dim
. Cells were incubated with Alexa-488 secondary antibody (only) 
and DAPI. (B) Fluorescence single cell images (original magnification 60 x) of human 
39 
blood cells sorted for VPC-11 (AC133
+
), VPC-5 (AC133
+
/CD31
+
), VPC-4 
(AC133
+
/CD34
+
/CD31
+
/CD45
+
), VPC-14 (AC133
+
/CD34
+
/CD45
+
), VPC-6 
(CD31
+
/CD34
+
), VPC-1 (CD31
+
/CD34
+
/CD45
dim
), VPC-7 
(CD31
+
/CD34
+
/CD45
dim
/AC133
–
), VPC-2 (CD31
+
/CD34
+
/CD45
+
), and VPC-8 
(CD31
+
/CD34
+
/CD45
+
/AC133
–
). Sorted cells were fluorescence labeled with Alexa-488-
Id-1 and DAPI and merged images of cells show colocalization of Id1 (Alexa-488-Id-1) 
with the nucleus (DAPI). (C) Fluorescence images (original magnification 60 x) of 
human umbilical vein endothelial cells (HUVEC) fluorescence labeled with Alexa-488-
Id-1 and DAPI (left image) or incubated with Alexa-488 secondary antibody (only) and 
DAPI (right). 
 
 
 
Table 2. Comparison between the low- and high- FRS risk populations. 
The low FRS category has a FRS < 20. The high FRS category has a FRS ≥ 20 or has 
experienced a cardiovascular event. VPC counts per µL sample. Fibrinogen units 
(mg/dL). Platelet mononuclear cells are the percent total of cells CD41
+
/45
+
. HsCRP 
units (mg/L). ** = significant at the 0.05 level. 
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Table 3. Comparison between the low- and high- CVD risk factor populations. 
The low-risk population has ≤ 1 Framingham risk factor for CVD among age ≥ 40 years, 
male gender, hypertension, hyperlipidemia, diabetes, and current smoking. The high-risk 
population has ≥ 2 Framingham risk factors. VPC counts per µL sample. Fibrinogen units 
(mg/dL). Platelet mononuclear cells are the percent total of cells CD41
+
/45
+
. HsCRP 
units (mg/L). ** = significant at the 0.05 level. 
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Table 4. Demographic comparison stratified by VPC-3 tertile. 
Low VPC-3 mean = -3095 ± 980.15, range = --6075 – -2030 (log-transformed VPC-3 
normalized to uL sample *1000). Medium VPC-3 mean = -1452 ± 299.7, range = -2008 – 
-878.5. High VPC-3 mean = -143.2 ± 532.2, range = -828.5 – 1589. Current, never, and 
former smokers based on self-report. Environmental smoke is secondhand smoke 
exposure in self-reported non-smokers. FRS = Framingham Risk Score. High FRS 
42 
category has a FRS ≥ 20 or experienced a cardiovascular event. BMI = body mass index. 
CABG = coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE = 
angiotensin-converting-enzyme. Age in years. Cotinine units (ng/mL). Fibrinogen units 
(mg/dL). HsCRP units (mg/L). Vasodilators included nitrates and hydralazine. Platelet 
mononuclear cells are the percent total of cells CD41
+
/45
+
. Median household income in 
USD at the US Census block group level. ** = significant at the 0.05 level.
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Table 5. Demographic comparison stratified by VPC-5 tertile. 
Low VPC-5 mean = -1414 ± 655.1, range = -3361 – -631.5 (log-transformed VPC-5 
normalized to uL sample *1000). Medium VPC-5 mean = -233.5 ± 201.2, range = -622.3 
– 68.22. High VPC-5 mean = 818.0 ± 757.8, range = 69.53 – 3968. Current, never, and 
former smokers based on self-report. Environmental smoke is secondhand smoke 
exposure in self-reported non-smokers. FRS = Framingham Risk Score. High FRS 
category has a FRS ≥ 20 or experienced a cardiovascular event. BMI = body mass index. 
CABG = coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE = 
44 
angiotensin-converting-enzyme. Age in years. Cotinine units (ng/mL). Fibrinogen units 
(mg/dL). HsCRP units (mg/L). Vasodilators included nitrates and hydralazine. Platelet 
mononuclear cells are the percent total of cells CD41
+
/45
+
. Median household income in 
USD at the US Census block group level. ** = significant at the 0.05 level. 
 
 
 
Table 6. Association between VPCs and FRS Category. 
The β presented is the adjusted β for the FRS Category. Models were adjusted for 
ethnicity, alcohol, BMI, and SES. 
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Figure 3. Adjusted association between VPCs and fibrinogen. 
The β presented is the adjusted β for fibrinogen. (A) Models were adjusted for 
hypertension, hyperlipidemia, diabetes, smoking, age, ethnicity, alcohol, gender, BMI, 
and SES. (B) Predicted value of mean VPC-1 was calculated form the adjusted regression 
model. (C) Predicted value of mean VPC-3 was calculated form the adjusted regression 
model. (D) Predicted value of mean VPC-13 was calculated form the adjusted regression 
model. (E) Predicted value of mean VPC-15 was calculated form the adjusted regression 
model.  
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Figure 4. Adjusted association between VPCs and platelet mononuclear cell 
aggregates. 
Platelet mononuclear cell aggregates are the percent total of cells CD41
+
/45
+. The β 
presented is the adjusted β for platelet mononuclear cell aggregates. (A) Models were 
adjusted for hypertension, hyperlipidemia, diabetes, smoking, age, ethnicity, alcohol, 
gender, BMI, and SES. (B) Predicted value of mean VPC-6 was calculated form the 
adjusted regression model. (C) Predicted value of mean VPC-9 was calculated form the 
adjusted regression model. (D) Predicted value of mean VPC-14 was calculated form the 
adjusted regression model.
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Figure 5. Adjusted association between VPCs and hsCRP. 
People with hsCRP > 10 were excluded from analysis (n=19). The β presented is the 
adjusted β for hsCRP. (A) Models were adjusted for hypertension, hyperlipidemia, 
diabetes, smoking, age, ethnicity, alcohol, gender, BMI, and SES. (B) Predicted value of 
mean VPC-5 was calculated form the adjusted regression model. (C) Predicted value of 
mean VPC-11 was calculated form the adjusted regression model.
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CHAPTER II 
Contribution of Acrolein to Cardiovascular Disease Risk and Vascular Progenitor 
Cell Levels 
Introduction 
Cardiovascular disease (CVD) is the leading cause of death in the U.S. 
1
. Vascular 
progenitor cells (VPCs) are suspected to be a sensitive indicator of vascular health. 
Several investigators have reported that decreased levels of circulating VPCs, cells that 
participate in vascular upkeep and repair, are associated with increased CVD risk 
63, 65, 69
, 
severity 
66, 71-73
, and mortality 
74
. Exposure to ambient air pollution, including particulate 
matter, is associated with increased CVD incidence and mortality 
29
, prompting a 
scientific statement from the American Heart Association indicating that air pollution 
exposure should be considered a modifiable risk factor for CVD 
32
. It has been recently 
shown that exposure to elevated levels of combustion pollutants, including fine 
particulate matter in healthy young adults 
30
 and acrolein in mice 
51
, decrease circulating 
VPC levels. Therefore, we investigated the association between acrolein and VPC levels 
in humans. 
Emerging evidence suggests that VPC populations may provide a mechanistic 
link between combustion pollutant exposure and CVD. The endothelium mediates 
vasodilatation and thrombosis. In mice, combustion pollutant exposure is associated with 
decreased endothelial-mediated vasodilation 
29
. In humans, exposure to combustion 
pollutants is associated with vasoconstriction 
29
, reduced brachial artery diameter 102, and 
49 
flow mediated vasodilation 
103, 104
. VPCs are necessary for upkeep and repair of the 
endothelium 
26
, participating in revascularization. Decreased VPC levels are associated 
with endothelial dysfunction, a hallmark of atherosclerosis development and a key 
mechanism in myocardial infarction 
27
. VPCs are heterogeneous populations, and 
understanding which phenotypically distinct population is associated with acrolein 
metabolism may be important in characterizing risk. 
Acrolein exposure is ubiquitous and includes multiple sources of exposure, 
including tobacco smoke, vehicular exhaust, open fires, and industrial emissions 
51
. 
Increased acrolein exposure is associated with increased CVD risk, including 
hypertension, atherogenesis, decreased plaque stability, suppression of cardiac flow, 
thrombosis, and cardiac contractility 
48
. Acrolein exposure in mice is associated with 
dyslipidemia, decreased VPC levels, and endothelial dysfunction 
49-51
. Additionally, 
protein-acrolein adducts have been found in atherosclerotic lesions in the vessels of 
acrolein-exposed mice 
51
. While acrolein promotes atherogenesis via protein adduct 
formation and oxidation of  thioredoxins in human endothelial cells,
48
 its effects on 
human VPCs are unknown. We explored the association between VPCs and acrolein 
using hydroxypropylmercapturic acid (HPMA), the acrolein metabolite found in highest 
quantity in the urine, and produced only by acrolein metabolism 
46
. Because tobacco 
smoke is a source of acrolein exposure and a risk factor for CVD, we also measured urine 
cotinine, the primary nicotine metabolite, to reduce potential confounding.  
Our objective was to examine the relationship between CVD risk and levels of the 
acrolein metabolite, HPMA. To characterize risk, we investigated VPC levels and 
markers of inflammation and thrombosis along with the Framingham Risk Score (FRS) to 
50 
indicate clinical risk prediction – a novel assessment in the field. We hypothesized that 
acrolein metabolism is inversely associated with VPC levels, thereby contributing to 
CVD risk.  
Methods 
Study Population 
See Overall Methods (Study Population). 
Case Definition 
See Overall Methods (Case Definition).  
Questionnaire 
See Overall Methods (Questionnaire). 
Biological Sample Collection and Processing 
See Overall Methods (Biological Sample Collection and Processing). 
VPC Quantification 
See Overall Methods (VPC Quantification). 
Platelet Mononuclear Cell Aggregate Identification 
See Overall Methods (Platelet Mononuclear Cell Aggregate Identification). 
HPMA Quantification 
We measured HPMA in urine using mass spectrometric analysis following the 
methods described by Carmella et al. 
105
 and modified by Conklin et al. 
46
. One mL of 
urine was combined with 2.5 nmol of C
13
 HPMA (internal standard) and added to an 
Oasis Max Solid Phase Extraction column for purification. The column protocol included 
sequentially applying: 6 mL MeOH, 6 ML 2% NH4OH, urine, 6 mL 2% NH4OH, and 6 
mL MeOH. The column was dried with N2 and then washed with 6 mL 2% formic acid. 
51 
Finally, it was eluted with 30% MeOH in 2% formic acid. The HPMA fraction was 
lyophilized and reconstituted in 1 mL of water. The solution was then syringe filtered and 
purified using high-performance liquid chromatography (HPLC). The HPMA fraction 
was lyophilized and subsequently derivitized with 40 µL acetonitrile and 40 µL N,O-
Bis(trimethylsilyl)trifluoroacetamide (BSTFA) for 1 hour at 60
o
C. One µL of the sample 
was applied to the gas chromatography / mass spectrometry (GC/MS) (Agilent 6890N) 
for quantification. The ion fragments 366 (HPMA) and 369 (C
13
 HPMA) were compared 
for quantification. HPMA values were normalized to creatinine, which was measured in 
urine using the Cobas Mira 5600 Autoanalyzer.  
Cotinine Quantification 
Cotinine was measured in urine using GC/MS following the methods described 
by Man et al. 
56
. See Overall Methods (Cotinine Quantification). 
Statistical Analysis 
Descriptive statistics were computed to describe the Healthy Heart Study 
population and are presented as n (%) for categorical variables and mean (SD) for 
continuous variables. Population demographics, CVD risk factors, markers of thrombosis 
(fibrinogen and platelet mononuclear cell aggregates), and markers of inflammation 
(hsCRP) were compared among tertiles representing low, medium, and high HPMA 
levels. The tertiles were formed by dividing the population’s HPMA levels into 3 even 
cut points. Population characteristics were compared using one-way analysis of variance 
(ANOVA) techniques for continuous variables and χ-squared analysis for dichotomous 
or categorical variables. 
52 
VPC levels were compared among the HPMA tertiles using ANOVA techniques. 
The VPC levels assessed were log transformed for normality, consistent with previous 
literature 
74
. VPC values presented are the VPC counts normalized to sample volume for 
consistency.  
To explore the relationship between HPMA and smoking, independent sample t-
test techniques were used to test for bivariate associations between self-reported smoking 
status and mean cotinine levels along with cotinine strata and mean HPMA levels. 
Cotinine was stratified into 2 strata representing low (cotinine < 200 ng/mL) and high 
(cotinine ≥ 200 ng/mL) smoking levels. These values are commonly used in the insurance 
industry to distinguish non-smokers from smokers. Additionally, HPMA was regressed 
against cotinine to verify the relationship between smoking and HPMA. 
To explore the relationship between HPMA and CVD risk, HPMA was regressed 
against the FRS. In the current database, the FRS was only determined for the primary 
prevention population. As such, to include the secondary population, we divided the 
entire population into 2 FRS categories. The low FRS category includes the population 
with an FRS < 20, while the high FRS population includes the population with an FRS ≥ 
20 and the population that has experienced a cardiovascular event (i.e. the secondary 
preventive population). Independent samples t-tests were also used to examine 
differences in HPMA levels between the 2 FRS categories in both the whole population 
and subsequently for the subset of non-smokers. 
Generalized Linear Modeling (GLM) techniques were used to examine whether 
the circulating VPC levels, markers of inflammation and thrombosis, and the FRS were 
associated with HPMA levels; after adjusting for age, gender, ethnicity, cotinine, alcohol 
53 
consumption, body mass index (BMI), hypertension, diabetes, diuretics, and vasodilators. 
The FRS and FRS category were only adjusted for ethnicity, alcohol consumption, and 
BMI (the remaining variables are included in the FRS equation). Because the VPC levels 
appeared to follow a gamma distribution, GLMs that assessed VPCs as the dependent 
variable utilized the gamma probability distribution and the log link function. For FRS 
Category the binomial distribution was used. All other GLMs utilized the normal 
probability distribution and the identity link function. Traditional model fit statistics (log-
likelihood) were used to develop the most parsimonious model. In addition we tested 
whether higher order modeling (e.g., exponential, cubic) improved model fit using 
traditional model-fit statistics (AIC, log-likelihood, etc.). Additionally, as an exploratory 
analysis, the aforementioned analysis was repeated in non-smokers to demonstrate the 
association with acrolein metabolism in the absence of smoke exposure. 
Results 
Participant Characteristics 
The sample population was middle-aged (51 years old), majority male (n=111, 
52.6%), Caucasian (n=120, 56.9%) and either a current smoker (n=82, 39.2%) or former 
smoker (n=71, 33.8%). A majority of the sample population had hypertension (n=168, 
81.2%); hyperlipidemia (n=131, 63.6%); were obese (BMI ≥ 30, n=118, 57.6%); or using 
angiotensin-converting-enzyme (ACE) inhibitors (n=112, 54.4%), beta-blockers (n=129, 
62.6%), or statins (n=109, 52.9%) (Table 7). 
Non-smoking Participant Characteristics 
The non-smokers in the sample population were middle-aged (53 years old), a 
majority male (n=68, 53.5%), Caucasian (n=73, 57.5%), and were either a former smoker 
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(n=71, 55.9%) or a never smoker (n=56, 44.1%). A majority of the non-smoking sample 
population had hypertension (n=103, 81.7%); hyperlipidemia (n=78, 61.4%); were obese 
(BMI ≥ 30, n=74, 59.7%); or using angiotensin-converting-enzyme (ACE) inhibitors 
(n=68, 55.3%), beta-blockers (n=79, 64.2%), or statins (n=64, 52.0%) (Table 8). 
Demographic Comparison 
Differences between the characteristics of the populations within low, medium, 
and high HPMA tertiles are shown in Table 7. There were no significant differences 
between HPMA tertile and gender; hypertension; hyperlipidemia; diabetes mellitus; 
environmental tobacco smoke; myocardial infarction; stroke; heart failure; most 
medications except diuretics; age; the FRS (in primary preventive patients); lymphocyte 
count; thrombosis, inflammation, and median household income. Caucasians were more 
likely to have higher HPMA than African Americans (p=0.005). Obese (BMI ≥ 30) 
participants had lower HPMA (p=0.015). Smoking demonstrated highly significant 
associations with HPMA; high HPMA was associated with self-report of being a current 
smoker (p<0.001), inversely associated with having never smoked (p=0.001) and being a 
former smoker (p<0.001), and was associated with higher cotinine levels (p<0.001). 
Participants in the high FRS category (FRS ≥ 20 or experienced a cardiovascular event) 
had significantly higher HPMA (p=0.006). Participants with revascularization including 
coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or stents 
also had higher HPMA (p=0.040) Participants who were taking diuretics had lower 
HPMA (p=0.005). 
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Non-smoking Demographic Comparison 
Differences between the characteristics of the non-smoking population within 
low, medium, and high HPMA tertiles are shown in Table 8. Obese (BMI ≥ 30) 
participants were less likely to have high HPMA (p=0.033). People with high HPMA 
were more likely to self-report having never smoked (p=0.015) and less likely to be a 
former smoker (p=0.015), and more likely to have higher cotinine (p<0.001). Participants 
that were taking diuretics were more likely to have low HPMA (p=0.023). People with 
low HPMA had a significantly a higher mean hsCRP level (p=0.004). 
Association between VPCs and CVD Risk with HPMA Tertile 
Results of the ANOVA comparison between HPMA tertile and VPC levels are 
shown in Table 9. VPC-2 ((CD31
+
/34
+
/45
+
); p=0.030), and VPC-8 
((CD31
+
/34
+
/45
+
/AC133
–
), p=0.035) were inversely associated with HPMA levels. When 
stratified into self-reported non-smokers, none of the VPC populations were significantly 
associated with HPMA tertile (Table 10). 
Association between Smoking and HPMA 
Associations between smoking and HPMA are illustrated in Figure 6. Mean 
cotinine levels were significantly higher in smokers when compared to non-smokers 
(1033.79 ± 93.84 v. 142.26 ± 37.78, p<0.001). Mean HPMA levels were significantly 
higher in the population with high cotinine (<200ng/mL) than low cotinine (≥200 
ng/mL), with values of 726.49 ± 74.61 and 144.93 ± 16.40 µg/g creatine (p<0.001), 
respectively. Regression analysis results confirmed that HPMA levels were positively 
associated with cotinine (β=0.257, R2=0.422, p<0.001). 
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Association between CVD Risk and HPMA 
Association between the FRS and HPMA are shown in Figure 7. A scatterplot 
demonstrates that HPMA levels increase as the FRS increases in the primary prevention 
population (R
2
=0.101, p=0.021). In a scatterplot of the primary preventive population of 
non-smokers, there is no significant association between HPMA and FRS (R
2
=0.010, 
p=0.595). The population in the low FRS category (FRS < 20) demonstrates significantly 
lower HPMA than the high FRS category (FRS ≥ 20 or experienced a cardiovascular 
event) with values of 181.45 ± 46.74 and 458.73 ± 30.04 µg/g creatine (p<0.001), 
respectively.  When stratified into the non-smoking population, although HPMA was 
about half that of the total population, HPMA remained significantly higher in the high 
FRS category with mean values of 105.16 ± 23.04 and 220.87 ± 26.69 µg/g creatine 
(p=0.001) for the low and high FRS categories, respectively. 
Adjusted Association of CVD Risk and HPMA 
The adjusted GLM results of CVD risk and HPMA are shown in Table 11. The 
associations were adjusted for age, gender, ethnicity, cotinine, alcohol, BMI, 
hypertension, diabetes, and diuretics. VPC-2 ((CD31
+
/34
+
/45
+), β=-0.002, p<0.001), 
VPC-8 ((CD31
+
/34
+
/45
+
/AC133
–
), β=-0.002, p<0.001), VPC-11 ((AC133+), β=-0.001, 
p=0.046), and VPC-14 ((CD34
+
/45
+
/AC133
+
), β=-0.002, p=0.029) were inversely 
associated with HPMA. Platelet mononuclear cell aggregates (CD41
+
/45
+
) were 
positively associated with HPMA (β=0.003, p=0.030). The FRS was associated with 
HPMA (β=0.012, p<0.001) after adjustment for ethnicity, alcohol, and BMI (the 
remaining variables are reflected in the FRS). The FRS category, also adjusted for 
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ethnicity, alcohol, and BMI, demonstrated a positive association with HPMA where the 
low FRS category had lower HPMA (β=-0.003, p=0.002).  
Adjusted Association of CVD Risk and HPMA in Non-smokers 
The adjusted GLM results of CVD risk and HPMA in non-smokers are shown in 
Table 12. The associations were adjusted for age, gender, ethnicity, cotinine, alcohol, 
BMI, hypertension, diabetes, and diuretics. VPC-2 ((CD31
+
/34
+
/45
+), β=-0.003, 
p<0.001), VPC-8 ((CD31
+
/34
+
/45
+
/AC133
–
), β=-0.003, p<0.001), VPC-9 (CD34+; β=-
0.001, p=0.024), and VPC-14 ((CD34
+
/45
+
/AC133
+
), β=-0.011, p=0.001) were inversely 
associated with HPMA; however, VPC-11 ((AC133
+
), β<0.001, p=0.793) was no longer 
associated with HPMA.  Platelet mononuclear cell aggregates (CD41
+
/45
+
) were no 
longer associated with HPMA (β=0.004, p=0.245). The FRS was no longer associated 
with HPMA (β=0.010, p=0.097) after adjustment for ethnicity, alcohol, and BMI. The 
FRS category was no longer associated with HPMA (β=-0.004, p=0.069).  
Discussion 
While associations between acrolein exposure and CVD risk have been shown in 
mice, this is the first study to examine the association between the primary urine acrolein 
metabolite, HPMA, and VPC levels as a measure of CVD risk in humans. The current 
results demonstrate a significant association with HPMA and ethnicity. Obese individuals 
were more likely to have low HPMA. Additionally, an inverse association between 
HPMA and use of diuretics was observed. Comparison between HPMA tertiles 
demonstrated that VPC-2 (CD31
+
/34
+
/45
+
) and VPC-8 (CD31
+
/34
+
/45
+
/AC133
–
) levels 
significantly decrease as HPMA levels increase. We verified that smokers have 
significantly higher HPMA levels, which was expected because cigarette smoke is a 
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source of acrolein. Our results demonstrated that HPMA is positively associated with the 
FRS and the FRS categories, indicating that HPMA levels significantly increase as risk 
increases. This association was consistent among FRS categories in non-smokers, 
suggesting that the association is not driven solely by tobacco smoke exposure. In the 
fully adjusted models, we determined that HPMA was significantly inversely associated 
with VPC-2, VPC-8, VPC-11 (AC133
+
), and VPC-14 (CD34
+
/45
+
/AC133
+
). 
Additionally, HPMA was significantly positively associated with thrombosis (platelet 
mononuclear cell aggregate levels), the FRS, and FRS categories. VPC-2, VPC-8, VPC-9 
(CD34
+
), and VPC-14 and significantly associated with HPMA when the models 
included non-smokers only. 
One particularly interesting finding was that Caucasians are more likely to have 
higher HPMA than African Americans in the Healthy Heart Study population. There was 
not a significant difference between smoking (empirical or self-reported) and ethnicity 
among the study participants. African Americans participants were also more likely to be 
obese, and HPMA levels decreased as BMI increased. The likely link between HPMA 
and ethnicity is diuretic use. There is a significantly higher proportion of African 
Americans using diuretics compared to Caucasians in the Healthy Heart Study, and we 
found that diuretic use decreased as HPMA tertile increased. There was not a significant 
association between smoking and BMI, and there was no association between HPMA and 
self-reported exercise. There was an association between BMI and diuretics, where obese 
patients were significantly more likely to be taking diuretics. When the population using 
diuretics is excluded from analysis, there is no longer a significant association between 
HPMA and BMI. Therefore, our adjusted regression model included diuretics as a 
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potential confounder. Future research should investigate other factors among different 
ethnicities and relating to BMI that may contribute to differences in HPMA levels. 
VPC-2 (CD31
+
/34
+
/45
+
), VPC-8 (CD31
+
/34
+
/45
+
/AC133
–
), and VPC-14 
(CD34
+
/45
+
/AC133
+
) levels were inversely associated with HPMA in both the total 
population and non-smokers. O’Toole et al. found that VPC-2 was inversely associated 
with increased exposure to PM2.5 
30
. Because VPC-8 is a sub-population of VPC-2, it is 
likely that VPC-8 is driving the association seen with VPC-2; therefore, the true 
association appears to be with VPC-8 and HPMA. The VPC-8 population should be 
assessed in future environmental research as a sensitive indicator of CVD risk and 
combustion pollution exposure, which could potentially provide insight into 
environmental mechanisms of vascular toxicity. 
We found that platelet mononuclear cell aggregates were positively associated 
with HPMA, suggesting that thrombosis increases as acrolein (a combustion pollutant) 
exposure increases. These results were similar to the finding by O’Toole et al. that 
increased combustion pollutant exposure (PM2.5) was associated with increased platelet 
mononuclear cell aggregates in healthy young adults 
30
. Our population of middle-aged 
adults with increased CVD risk demonstrated a similar association with acrolein 
metabolism. 
This is the first investigation to report an association between HPMA and FRS. 
Because the FRS includes smoking, and smoking is a source of acrolein, we also 
analyzed the association with the FRS and HPMA in non-smokers. The positive 
association between HPMA and FRS category remained in the non-adjusted comparisons 
in the whole population as well as the non-smoking population. This suggests that the 
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association between HPMA and FRS may not be driven entirely by tobacco smoke 
exposure, but also possibly by acrolein through the environment, endogenous exposure, 
or in food. In the adjusted analyses, HPMA no longer remained significantly lower in the 
low FRS category when assessing the whole population nor the non-smoking population. 
To further understand the environmental contribution, ambient or personal monitoring of 
acrolein will be necessary.  
Strengths of the current study include the large study population with a wide 
range of CVD risk factors, allowing us to investigate how differences in risk factors are 
associated with HPMA. Additionally, our study includes multiple phenotypically 
different VPC populations to understand which cell types are associated HPMA. This 
expands on past VPC research by understanding differences in the phenotypes associated 
with environmental exposures. The endothelial cell (CD31
+
), stem cell (CD34
+
), 
hematopoietic cell (CD45
+
), and early and late stem cell  (AC133
+/ –
) phenotypes 
demonstrated significantly lower levels with increased HPMA concentrations. The 
progenitor cell populations with the non-hematopoietic (CD45
dim
) cell phenotype were 
not associated with acrolein metabolism, a novel finding in combustion pollution-linked 
vascular research. An added benefit of our study was that we were able to account for 
potential confounding by measuring cotinine levels, the primary urine nicotine 
metabolite, in addition to collecting data on self-reported smoking. We adjusted for 
potential confounding due to diuretic use, which was associated with ethnicity and BMI. 
One potential limitation in this study is the lack of ambient acrolein 
measurements. Acrolein is highly volatile, and the stationary acrolein monitors are not 
widely dispersed throughout Jefferson County, KY to attain a valid estimation of 
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exposure levels in our study population. An additional limitation is that investigations of 
urine metabolites generally collect urine at the first catch. Our study collected urine (for 
HPMA and cotinine) and blood (for VPCs and markers of inflammation and thrombosis) 
at the time of the visit (between 9 am and 5 pm). Similarly, some of the research on VPCs 
indicates that they demonstrate diurnal variations and recommend that blood should be 
collected at the same point each day 
64
. Our collection of blood and urine at the same time 
point did allow a snapshot of collective exposures and risk from that corresponding point 
in time. Some of the limitations to the investigation involve the type of study we have 
selected. Cross-sectional studies are limited in their ability to demonstrate causality, but 
are useful to identify associations that can be used to generate hypotheses for future 
cohort studies. Moreover, none of the recruiting personnel fluently spoke languages other 
than English; therefore, some potential participants without a translator present were not 
able to provide consent for the study or participate in the interview questionnaire. In 
addition, based on the recruitment being entirely from cardiology clinics, we lacked a 
true population-based sample, but rather an at-risk population. This poses a limitation in 
being able to generalize the results to the larger community. 
For future directions of this research, it would be beneficial to measure ambient 
acrolein levels, in order to determine the portion of HPMA that may be attributed to 
environmental exposure. Understanding the basis for the differences in HPMA among 
different ethnicities and obesity will be valuable in characterizing risk. We could also 
investigate other biomarkers of environmental exposures to determine how they affect 
CVD risk and VPC levels. A future case-control study with controls that have no CVD 
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and are non-smokers would be beneficial to better understand differences in risk and 
acrolein metabolite levels. 
In summary, these findings suggest that increased HPMA levels are associated 
with increased CVD risk. The major finding in the current study is that acrolein 
metabolism appears to be associated with vascular injury, as reflected by reduced VPC 
levels. This is accompanied by increased CVD risk and thrombosis. VPC-2 and VPC-8 
levels were significantly lower with increased HPMA levels. Because VPC-8 is a sub-
population of VPC-2, it is likely that VPC-8 (specifically the AC133
–
 late stem cell 
phenotype) is driving the association. Additionally, VPC-11 and VPC-14 were inversely 
associated with HPMA. A marker of thrombosis was significantly higher with increased 
HPMA. Lastly, as the FRS increased, HPMA levels increased. The associations seen in 
VPC-2, VPC-8, VPC-9, and VPC-14 were associated among the non-smoking 
population, suggesting that environmental exposure to acrolein poses additional 
endothelial risk that is detectable through these VPC populations. 
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Figures and Tables 
 
 
Table 7. Demographic comparison stratified by HPMA tertile. 
Low HPMA mean = 54.89 ± 17.76, range = 19.11-87.29 μg/g creatinine. Medium HPMA 
mean = 202.50 ± 100.37, range = 87.81 – 405.23 μg/g creatinine. High HPMA mean = 
940.12 ± 693.73, range = 424.03 – 4908.19 μg/g creatinine. Current, never, and former 
64 
smokers based on self-report. Environmental smoke is secondhand smoke exposure in 
self-reported non-smokers. BMI = body mass index. FRS = Framingham Risk Score. 
High FRS category has a FRS ≥ 20 or experienced a cardiovascular event. CABG = 
coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE = 
angiotensin-converting-enzyme. Age in years. Cotinine units (ng/mL). Fibrinogen units 
(mg/dL). HsCRP units (mg/L). Vasodilators included nitrates and hydralazine. Platelet 
mononuclear cells are the percent total of cells CD41
+
/45
+
. Median household income in 
USD at the US Census block group level. ** = significant at the 0.05 level. 
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Table 8. Demographic comparison stratified by HPMA tertile in non-smokers. 
Low HPMA mean = 54.89 ± 17.76, range = 19.11-87.29 μg/g creatinine. Medium HPMA 
mean = 202.50 ± 100.37, range = 87.81 – 405.23 μg/g creatinine. High HPMA mean = 
940.12 ± 693.73, range = 424.03 – 4908.19 μg/g creatinine. Current, never, and former 
smokers based on self-report. Environmental smoke is secondhand smoke exposure in 
self-reported non-smokers. BMI = body mass index. FRS = Framingham Risk Score. 
High FRS category has a FRS ≥ 20 or experienced a cardiovascular event. CABG = 
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coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE = 
angiotensin-converting-enzyme. Age in years. Cotinine units (ng/mL). Fibrinogen units 
(mg/dL). HsCRP units (mg/L). Vasodilators included nitrates and hydralazine. Platelet 
mononuclear cells are the percent total of cells CD41
+
/45
+
. Median household income in 
USD at the US Census block group level. ** = significant at the 0.05 level. 
 
 
 
 
 
Table 9. Comparison of VPC levels among HPMA tertiles. 
VPC counts per µL sample. ** = significant at the 0.05 level. 
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Table 10. Comparison of VPC levels among HPMA tertiles in non-smokers. 
VPC counts per µL sample. ** = significant at the 0.05 level.
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Figure 6. Association between HPMA and smoking. 
(A) Mean cotinine for self-reported non-smokers was 145.26 ± 37.78 and 1033.79 ± 
93.84 ng/mL for smokers. (B) Mean HPMA levels for low (<200 ng/mL) and high (≥200 
ng/mL) cotinine strata were 144.93 ± 16.40 and 726.49 ± 74.61 ug/g creatinine, 
respectively. (C) HPMA regressed against cotinine levels. 
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Figure 7. Association between HPMA and the FRS. 
A) Scatterplot of HPMA and FRS. (B) Scatterplot of HPMA and FRS in self-reported 
non-smokers. (C) Mean HPMA levels for low (FRS < 20) and high (FRS ≥ 20) or 
experienced a cardiovascular event FRS category were 181.45 ± 46.74 and 453.73 ± 
30.04 μg/g creatinine, respectively. (D) Mean HPMA levels for low and high FRS 
categories in self-reported non-smokers were 105.16 ± 23.04 and 220.87 ± 26.69 μg/g 
creatinine, respectively. 
70 
 
 
Table 11. Adjusted association between HPMA and CVD Risk. 
Models were adjusted for age, gender, ethnicity, cotinine, alcohol, BMI, hypertension, 
diabetes, and diuretics. FRS = Framingham Risk Score. GLMs that assessed VPCs as the 
dependent variable utilized the gamma probability distribution and the log link function. 
GLMs for platelet mononuclear cell aggregates and the FRS were assessed using normal 
probability distribution and the identity link function. The GLM for FRS category was 
analyzed using the binomial distribution. The FRS and FRS Category were only adjusted 
for ethnicity, alcohol, and BMI. 
 
 
 
Table 12. Adjusted association between HPMA and CVD Risk in non-smokers. 
Models were adjusted for age, gender, ethnicity, cotinine, alcohol, BMI, hypertension, 
diabetes, and diuretics in self-reported non-smokers. FRS = Framingham Risk Score. 
GLMs that assessed VPCs as the dependent variable utilized the gamma probability 
distribution and the log link function. GLMs for platelet mononuclear cell aggregates and 
the FRS were assessed using normal probability distribution and the identity link 
function. The GLM for FRS category was analyzed using the binomial distribution. The 
FRS and FRS Category were only adjusted for ethnicity, alcohol, and BMI.
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CHAPTER III 
The Association of Residential Proximity to Roadway with Circulating Vascular 
Progenitor Cell Levels 
Introduction 
Cardiovascular disease (CVD) is the top cause of death in the United States, 
responsible for 1 in every 3 deaths 
1
. Vascular progenitor cells (VPCs) are suspected to be 
a sensitive indicator of vascular health. Several investigators have reported that decreased 
levels of circulating VPCs, cells that participate in vascular upkeep and repair, are 
inversely associated with increased CVD risk 
63, 65, 69
, severity 
66, 71-73
, and mortality 
74
.  
Growing evidence of the associations between particulate matter exposure and CVD risk 
led to a scientific statement from the American Heart Association indicating that air 
pollution exposure should be considered a modifiable risk factor for CVD 
32
. It has been 
recently shown that exposure to elevated levels of vehicular exhaust pollutants, including 
fine particulate matter in healthy young adults 
30
 and acrolein in mice 
51
, were associated 
with decreased circulating VPC levels. Therefore, the association between traffic 
pollution exposure and VPC levels should be explored, particularly in a susceptible 
population of adults at increased risk for CVD. 
Traffic emissions include a mixture of particulate, gaseous, and volatile 
pollutants. It is assumed that people living closer to major roadways bear more exposure 
to these emissions. Epidemiological research indicates that living in close proximity to a 
major roadway, a common measure used to indicate traffic pollution exposure, is 
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associated with increased risk of CVD and CVD mortality. Close proximity to roadways 
has been associated with increased coronary heart disease mortality 37, 106, 107, myocardial 
infarction 
38, 108
, heart failure 
109
, deep vein thrombosis 
110
, and stroke mortality 
111
. C-
reactive protein (CRP), a clinical risk indicator, is positively associated with traffic 
density 112. In addition, inverse associations have been determined between roadway 
proximity and sub-clinical risk including coronary artery calcification 
39
 and oxidized 
low-density lipoprotein (LDL) 113. Investigation of the association between traffic 
pollution exposure and vascular outcomes at the cellular level may provide a greater 
understanding of the environment’s role in cardiovascular disease risk. 
Multiple studies have confirmed that traffic pollutants decrease in quantity as 
distance to roadway increases. Roorda-Knape et al. demonstrated that black smoke and 
NO2 background levels are reached at 300m of a roadway carrying a mean of 80,000-
152,000 vehicles/day 114. Zhu et al. 2002 reported that CO and particulate matter (PM) 
background concentrations were reached at 150m of a freeway with a mean of 13,900 
vehicles/hour 
115
. A meta-analysis determined that background concentrations are reached 
at 100–400m for PM, 200–500m for NO2, and 100–300m for ultrafine particulate matter 
(UPM) from mobile sources 
116
. Studies finding associations between roadway proximity 
and adverse cardiovascular outcomes generally consider people to be exposed within: 
100m of a limited-access highway or multilane highway 
108
; 300m of an interstate, state 
highway, or major arterial 
106
; and 50m of major arterial and 100m of an interstate or 
state highway 
117
. Our investigation provides a missing link in by examining associations 
within close proximity to a major roadway that carries a moderate mean number of 
vehicles per day (5000). We consider people within 50m of the roadway to be exposed.  
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While a substantial body of research has established that living in close proximity 
to a major roadway is associated with increased CVD morbidity and mortality, the impact 
of exposure to traffic pollution on VPC levels has not been assessed. Our objective was to 
investigate the association between residential proximity to a roadway and VPC levels as 
a measure of CVD risk. We hypothesized that residential proximity to roadway is 
associated with VPC levels in a population at increased risk for CVD. Residential 
addresses were geocoded to determine distance to roadway in a population of individuals 
at increased risk for CVD. VPC levels for 15 different antigenically-defined VPC 
populations were measured by flow cytometry to determine associations with residential 
proximity to a major roadway. This investigation evaluated the established association 
between roadway proximity and CVD risk through investigation of VPC levels, a novel 
assessment. 
Methods 
Study Population 
See Overall Methods (Study Population). 
Case Definition 
See Overall Methods (Case Definition).  
Questionnaire 
See Overall Methods (Questionnaire). 
Biological Sample Collection and Processing 
See Overall Methods (Biological Sample Collection and Processing). 
VPC Quantification 
See Overall Methods (VPC Quantification). 
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Platelet Mononuclear Cell Aggregate Identification 
See Overall Methods (Platelet Mononuclear Cell Aggregate Identification). 
Residential Proximity to Roadway 
Residential addresses of study participants were provided during the patient 
interview questionnaire or through the review of medical records. Distance to roadway 
measurements were carried out using Geographic Information System (GIS) ArcMap 9.3 
(ESRI, Redlands, CA). Data for geocoding addresses was provided by the 
Louisville/Jefferson County Information Consortium (LOJIC) composite locator in 
ArcGIS. Subject addresses were first examined for flaws including spelling errors, 
invalid characters, and invalid format, etc. Addresses that could not be geocoded were 
cross-referenced with other known addresses, or attempts were made to manually place 
the points. The records were examined for duplicates, which were most often apartments, 
condominiums, and mobile home communities. We examined aerial imagery and 
excluded records where the geocoded point was not at the residential location; many of 
these were mobile home communities or postal office boxes. Road vehicle counts were 
provided by the Kentucky Transportation Cabinet. Major roadway was defined as a road 
carrying an annual mean of 5,000 or more vehicles/day. Roadway proximity was entered 
into the statistical model as dichotomous data indicating living within 50m of a major 
roadway. Socioeconomic status (SES), estimated using the proxy variable “median 
household income,” was provided at the block group level from the 2000 U.S. Census. 
“Residential duration”, which indicates the length of time the home was owned by the 
current owner, was also included in the model. These housing records were available 
through the Jefferson County, KY Property Valuation Administrator via LOJIC. The final 
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model only included the population that had a residential duration at their current home 
of at least 6 months. 
PM2.5 Estimation 
Fine particulate matter (particulate matter with an aerodynamic diameter less than 
2.5μm; PM2.5) levels are collected hourly at 5 ambient monitoring stations within 
Jefferson County, KY. PM2.5 values were assigned by zip codes of the Healthy Heart 
Study participants. The PM2.5 monitor closest to the residential zip code was assigned to 
each participant. The hourly levels were averaged over 1 day prior to the sample 
collection.  
Statistical Analysis 
Independent samples t-tests (for normally distributed continuous variables), 
Wilcoxon methods (for non-normal continuous variables) and chi-square analysis (for 
categorical or dichotomous variables) were used to test for differences in the 
dichotomized version of the distance to a major roadway variable among gender, 
ethnicity, smoking status, CVD risk, CVD history, age, and median household income 
within the study population. 
Initially, independent sample t-test techniques were used to test for bivariate 
associations between the dichotomized version of distance to roadway and VPC levels, 
markers of thrombosis (platelet mononuclear cell aggregates and fibrinogen), markers of 
inflammation (hsCRP), the sum of risk factors (age ≥ 40 years, male gender, 
hypertension, hyperlipidemia, diabetes, and current smoking), and the Framingham Risk 
Score (FRS). VPCs were log-transformed * 1000 for normality in the t-test analysis, and 
the significance is reported. The mean cell levels, normalized to sample volume, are 
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presented in the results, consistent with the literature. The factors that were significantly 
associated with distance to roadway in the bivariate analysis were entered into the 
adjusted regression model below. 
Generalized Linear Modeling (GLM) techniques were used to examine whether 
the VPC values were associated with distance to a major roadway, adjusting for age, 
gender, body mass index (BMI), cigarette smoking, median household income (SES), and 
24-hour average PM2.5. Only the population with a residential duration of at least 6 
months was included in the final analysis to control for exposure misclassification. GLM 
models that assessed VPCs as the dependent variable utilized the gamma probability 
distribution and the log link function. GLMs that assessed the sum of risk factors utilized 
the normal probability distribution and the identity link function. Traditional model-fit 
statistics (log-likelihood) were used to develop the most parsimonious model. In addition 
we tested whether higher order modeling (e.g., exponential, cubic) improved model-fit 
using traditional model-fit statistics (AIC, log-likelihood, etc.). 
Results 
Participant Characteristics 
The sample population was middle-aged (51±10 years old), majority male 
(n=110, 54.2%), Caucasian (n=106, 52.2%) and was either a current smoker (n=78, 
38.8%) or former smoker (n=67, 33.2%). A majority of the sample population had 
hypertension (n=162, 81.4%); hyperlipidemia (n=126, 63.6%); were obese (BMI ≥ 30, 
n=118, 59.6%); and using angiotensin-converting-enzyme (ACE) inhibitors (n=111, 
55.5%), beta-blockers (n=127, 63.5%), and statins (n=101, 50.5%) (Table 13). We 
successfully geocoded n=203, 84.6% of the patient addresses. 
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Participant Characteristics of the Population with a Residential Proximity of 6 
Months 
The non-smoking sample population was middle-aged (52 years old), a majority 
male (n=57, 57%), Caucasian (n=53, 53.0%) and was either a current smoker (n=38, 
38%) or former smoker (n=37, 37%). A majority of the sample population had 
hypertension (n=84, 84.8%); hyperlipidemia (n=66, 68%); were obese (BMI ≥ 30, n=61, 
62.9%); and using angiotensin-converting-enzyme (ACE) inhibitors (n=57, 57.6%), beta-
blockers (n=72, 72.7%), and statins (n=61, 61.6%) (Table 14). Patients with cancer were 
excluded from the analysis (n=6). 
Geographic Distribution 
The geographic distribution of Healthy Heart Study participants in Jefferson 
County. KY is shown in Figure 8. The patients are largely concentrated in the 
northwestern region of Jefferson County known as West Louisville. It is also well known 
that this area suffers disproportionately from cardiovascular disease and air pollution 
exposure. 
Demographic Comparison 
Differences between the characteristics of the population living within 50m of a 
major roadway were compared to people living more than 50m from a major roadway are 
shown in Table 13. There were no significant differences between distance from a major 
road and the following factors: age, gender, ethnicity, hypertension, hyperlipidemia, 
diabetes mellitus, obesity, environmental tobacco smoke exposure, empirical smoke 
exposure (cotinine), myocardial infarction, stroke, coronary artery bypass graft (CABG)/ 
percutaneous coronary intervention (PCI)/ or stents, heart failure, or medication use.  
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People within 50m of a major road were more likely to self-report being a current smoker 
(53.8% vs. 35.2%, p=0.043) and less likely to report having never smoked (12.8% vs. 
31.5%, p=0.027). People with closer roadway proximity also had significantly higher 
lymphocyte counts (167,394 vs. 121,368, p=0.033) and significantly lower incomes 
($23,560 vs. $32,944, p=0.002). 
Demographic Comparison of the Population with a Residential Proximity of 6 
Months 
Differences between the characteristics of the population that lived within 50m of 
a major roadway were compared to people that lived more than 50m from a major 
roadway are shown in Table 14. People within 50m of a major road were more likely to 
self-report being a current smoker (71.4% vs. 32.6%, p=0.008), less likely to report 
having never smoked (0.0% vs.29.1%, p=0.019), and more likely to have a higher mean 
cotinine (1,059 ±1,136.vs. 456 ± 870 ng/mL, p=0.037).  Heart failure patients were 
significantly less likely to live near a major road (0.0% vs. 24.4%, p=0.037). People that 
lived in close proximity to a major road also had significantly lower incomes ($23,595 ± 
$6,900 vs. $34,457 ± $19,277, p=0.040). 
Association between VPCs and CVD Risk with Distance to Roadway 
Results of the independent-sample t-test comparison between dichotomized 
distance to roadway and VPC levels, markers of thrombosis (platelet mononuclear cell 
aggregates and fibrinogen), markers of inflammation (hsCRP), and CVD risk scores are 
shown in Table 15. VPC-4 ((CD31
+
/34
+
/45
+
/AC133
+
); p=0.047), VPC-5 
((CD31
+
/AC133
+
), p=0.007), VPC-11 ((AC133
+
), p=0.013), and VPC-14 
((CD34
+
/45
+
/AC133
+
), p=0.030) were significantly associated with distance to roadway; 
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these VPC levels were higher in the population that lived closer to a major roadway. The 
sum of CVD risk factors was inversely associated with residential proximity to roadway 
(p=0.017). 
Association between VPCs and CVD Risk with Distance to Roadway in the 
Population with a Residential Proximity of 6 Months 
Results of the independent-sample t-test comparison between dichotomized 
distance to roadway and VPC levels, markers of thrombosis (platelet mononuclear cell 
aggregates and fibrinogen), markers of inflammation (hsCRP), and CVD risk scores are 
shown in Table 16. There was no significant association between distance to roadway and 
VPC levels, thrombosis, inflammation, or CVD risk in the population with a 6 month 
residential duration. 
Adjusted Association of VPCs and Distance to Roadway for the Total Population 
The adjusted GLM results of VPCs and distance to roadway are shown in Table 
17. The associations were adjusted for age, gender, BMI, cigarette smoking, median 
household income, and 24-hour PM2.5. VPC-5 ((CD31
+
/AC133
+
), β=-0.648, p=0.003), 
VPC-11((AC133
+
), β=-0.469, p=0.033), and VPC-14 ((CD34+/45+/AC133+), β=-1.138, 
p=0.018) were significantly associated with distance to roadway. VPC levels in these 
populations were higher in the population that lived closer to a major roadway, as 
inferred from a negative regression coefficient. VPC-4 ((CD31
+
/34
+
/45
+
/AC133
+), β=-
0.611, p=0.083) was not significantly associated with distance to roadway. The sum of 
CVD risk factors was inversely associated with residential proximity to roadway (β=-
0.517, p=0.021), after adjustment for BMI, median household income, and 24-hour PM2.5 
(not age, gender, smoking which are risk factors themselves). 
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Adjusted Association of VPCs and Distance to Roadway in the Population with a 
Residential Proximity of 6 Months 
As previously described, only the population with a residential duration of at least 
6 months was included in the final analysis. The adjusted GLM results of VPCs and 
distance to roadway among individuals who resided in their homes for at least 6 months 
are shown in Table 18. The associations were adjusted for age, gender, BMI, cigarette 
smoking, median household income, and 24-hour PM2.5. Patients with cancer were 
excluded from the analysis. Among the population with a residential duration of at least 6 
months (n=80), VPC-4 ((CD31
+
/34
+
/45
+
/AC133
+), β=-1.333, p=0.005), VPC-5 
((CD31
+
/AC133
+
), β=-0.835, p=0.015), and VPC-14 ((CD34+/45+/AC133+), β=-1.037, 
p=0.015) remained significantly associated with distance to roadway. VPC levels in these 
populations were higher in the population that lived closer to a major roadway. VPC-
11((AC133
+
), β=-0.588, p=0.130), and the sum of CVD risk factors (β=-0.687, p=0.070 
(only adjusted for BMI, median household income, and 24-hour PM2.5 (not adjusted for 
age, gender, smoking which are risk factors themselves))) were no longer significantly 
associated with distance to roadway when stratifying by residential duration of at least 6 
months. These results held consistent when the model was adjusted for residential 
duration as a continuous variable, residential duration was entered as a dichotomous 
variable for 1 year residency, or stratified to include only the population with a residential 
duration of 1 year or more. 
Discussion 
Multiple investigators have reported inverse associations between residential 
proximity to roadways and CVD risk. However, the association between residential 
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proximity to a major roadway and VPC levels has not been investigated. Among a panel 
of 15 antigenically defined VPCs, we found that VPC-4 (CD31
+
/34
+
/45
+
/AC133
+
), VPC-
5 (CD31
+
/AC133
+
), VPC-11(AC133
+
), VPC-14(CD34
+
/45
+
/AC133
+
), and the sum of 
CVD risk factors were significantly higher in the population living in close proximity to a 
major roadway. In the adjusted analysis of the population with 6-month residency at their 
current home, VPC-4, VPC-5, and VPC-14 remained significantly higher in the 
population residing closer to the roadway. 
The results of the current study demonstrated that individuals that lived closer to 
the roadway had a higher number of CVD risk factors. This is consistent with previous 
studies which determined that individuals in close residential proximity to major roads 
have higher CVD risk 
37, 38, 106-108
. Moreover, the aforementioned result remained after 
adjustment for PM2.5, but not after stratification for 6 month residential duration. This 
suggests that CVD risk is associated with roadway proximity, independent of PM2.5 level. 
These results regarding VPC increases with decreased road proximity are 
biologically plausible. It has been demonstrated that inhalation of PM2.5 may cause 
pulmonary oxidative stress and inflammation, autonomic nervous system imbalance, and 
hemodynamic imbalances 
32, 118. Each of these pathways causes vascular outcomes that 
may result in mobilization of early progenitors (following acute exposure) or possibly 
depletion of VPCs after prolonged exposure. Our findings suggest that the associations 
with distance to roadway and VPCs are mostly seen in cells that are AC133
+
, the early 
stem marker. This could indicate that with a population at risk for CVD, living closer to 
the roadway leads to mobilization of early VPCs, possibly as a protective mechanism 
against environmental insults.  
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VPC levels increase following a vascular insult. They are mobilized into 
circulation to the site of injury to achieve their role in vascular repair. Faidini et al. 
described that as atherosclerosis progresses to an event in low risk populations, VPCs are 
mobilized into circulation, but this action can be limited in high risk populations where 
VPCs have been depleted 
80
. Furthermore, as the number of risk factors increase, it is 
more likely that individuals are being treated for primary prevention of CVD through 
statins which increase VPC levels 
64, 81, 87, 88
 and VPC mobilization.
89-91
. 
Although we determined that VPC levels are significantly increased in the 
population living in closer proximity to a major roadway, the adjusted regression model 
did find that PM2.5 was inversely associated with VPC levels in the population with 6 
month residency (cancer patients excluded), adjusted for age, gender, smoking, BMI, 
SES, and distance to a major roadway. VPC-5 (β=-0.048, p=0.009), VPC-11 (β=-0.063, 
p=0.003), VPC-14 (β=-0.062, p=0.047) were inversely associated with PM2.5. O’Toole et 
al. also determined that VPC levels were inversely associated with PM2.5 exposure during 
temperature inversions in Provo, UT 
30
. While the current population was relatively 
unhealthy in terms of CVD risk, the population in the study by O’Toole et al. was 
comprised of healthy collegiate athletes. The current study demonstrated VPC decreases 
associated just as the O’Toole et al. investigation. However, the current study was able to 
determine this with lower PM2.5 exposure levels. This suggests that even at lower PM2.5 
exposure levels, there are still detectable VPC reductions. 
Among the strengths of our study include the large study population. The range of 
CVD risk factors within our study population make it a diverse group to study. 
Additionally, our study includes multiple phenotypically distinct VPC populations to 
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understand which populations are associated with distance to roadway. We were able to 
account for potential confounding by measuring cotinine levels, the primary urine 
nicotine metabolite, in addition to collecting data on self-reported smoking. Cancer 
patients were excluded from the final analysis because VPCs are recruited in tumor 
angiogenesis 
75-77
, which may increase VPC levels (we did not find significantly different 
associations when including or excluding cancer patients in the final analysis). Including 
the residential duration in our sub-analysis allowed additional benefit in our 
understanding of VPC associations with road proximity because it allowed for reduced 
exposure misclassification in the population that had not resided at their homes for a 
long-term duration. 
One important limitation includes not accounting for some potential confounders 
in traffic exposure, including traffic noise, which has been associated with higher blood 
pressure 
119
 and increased risk of adverse cardiovascular outcomes 120, 121. It is also 
associated with distance to roadway; therefore, it is an important factor to consider in 
roadway proximity studies. Additionally, land use and tree cover, factors that can mediate 
or exacerbate traffic pollution exposure, were also not accounted for in the current study. 
Moreover, PM2.5 exposures were assigned by zip code, rather than inverse distance 
weighting or other interpolation methods. The use of road proximity as an indicator of 
exposure to traffic pollutants assumes that study participants spend much of their time at 
home. Therefore, it does not account for the duration of time individuals spend outside 
their home and road proximity during other activities. There was also no account for time 
spent in vehicles or participation in traffic, which has been associated with increased 
cardiovascular risk 
35
. Socioeconomic status (SES) is an important consideration in 
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cardiovascular research because of its association with adverse cardiovascular risk. The 
foremost measure of SES is maternal education, which was not assessed in the study 
questionnaire. We assessed median household income for the Census block group of the 
participant’s residential address to approximate SES. The duration of home ownership 
was helpful to account for exposure misclassification; however, we were unable to 
account for the population that rents property because that variable was not included in 
our study questionnaire. Additional limitations include the study design: a cross-sectional 
analysis of a convenience sample recruited from cardiology clinics. Therefore, the 
findings represent the CVD risk population in Louisville, KY and cannot be extrapolated 
to represent the general population, even in Louisville, KY.  
Future directions from this research should involve the inclusion of a CVD-free 
control population. More detailed information on residential address history and duration 
would be helpful to define exposures and inclusion of multiple study sites would be 
beneficial in understanding the differences between roads with higher or lower mean 
annual vehicles. Additionally, research into the mechanism by which traffic pollution 
exposure influences circulating VPC levels is needed. Determining which component of 
vehicular traffic pollution influences circulating VPC levels might also broaden our 
understanding of how the environment contributes to CVD. 
Conclusions 
The sum of CVD risk factors along with VPC-4 (CD31
+
/34
+
/45
+
/AC133
+
), VPC-5 
(CD31
+
/AC133
+
), VPC-11(AC133
+
), and VPC-14(CD34
+
/45
+
/AC133
+
) were elevated in 
the population that resided in closer proximity to the roadway. VPCs with the AC133
+
 
phenotype were higher in people who lived closer to a major road, suggesting that the 
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effects of traffic pollutants on the vascular system may be associated with increased 
circulation of AC133
+
 cells as a means of vasoprotection. The finding that the population 
in closer proximity to the road has higher levels of early progenitors is intriguing given 
our finding that CVD risk decreases with increased roadway distance. This suggests that 
the population living in close proximity to the road has higher risk and this may have 
stimulated VPCs into circulation. This is biologically plausible because increased risk 
alone may stimulate VPCs into circulation. 
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Figures and Tables 
 
Figure 8. Patients’ residential locations in Jefferson County, KY. 
Patient addresses are geographically masked.  
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Table 13. Demographics and CVD risk history stratified by roadway proximity. 
Current, never, and former smokers are based on self-report. Environmental smoke is 
self-reported secondhand smoke exposure in non-smokers only. BMI = body mass index. 
Cotinine units (ng/mL). CABG = coronary artery bypass graft. PCI = percutaneous 
coronary intervention. ACE = angiotensin-converting-enzyme. Vasodilators include 
nitrates and hydralazine. Median household income in USD at the US Census block 
group level. ** = significant at the 0.05 level.  
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Table 14. Demographics and CVD risk history stratified by roadway proximity in 
people with a residential duration of 6 months. 
Cancer patients (n=6) were excluded from this analysis. Current, never, and former 
smokers are based on self-report. Environmental smoke is self-reported secondhand 
smoke exposure in non-smokers only. BMI = body mass index. Cotinine units (ng/mL). 
CABG = coronary artery bypass graft. PCI = percutaneous coronary intervention. ACE = 
angiotensin-converting-enzyme. Vasodilators include nitrates and hydralazine. Median 
household income in USD at the US Census block group level. ** = significant at the 
0.05 level. 
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Table 15. Comparison of VPC levels, thrombosis, inflammation, and CVD risk 
between roadway proximities. 
VPC counts per µL sample. Fibrinogen units (mg/dL). Platelet mononuclear cell 
aggregates are the percent of total cells CD41
+
/45
+
. HsCRP units (mg/L). The sum of 
CVD risk factors includes the following Framingham risk factors: age ≥ 40 years, male 
gender, current smoker, hypertension, hyperlipidemia, and diabetes. ** = significant at 
the 0.05 level. 
 
  
 
 
90 
 
Table 16. Comparison of VPC levels, thrombosis, inflammation, and CVD risk 
between roadway proximities in people with a residential duration of at least 6 
months. 
Cancer patients (n=6) were excluded from analysis. VPC counts per µL sample. 
Fibrinogen units (mg/dL). Platelet mononuclear cell aggregates are the percent of total 
cells CD41
+
/45
+
. HsCRP units (mg/L). The sum of CVD risk factors includes the 
following Framingham risk factors: age ≥ 40 years, male gender, current smoker, 
hypertension, hyperlipidemia, and diabetes. ** = significant at the 0.05 level. 
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Table 17. Association between roadway proximity, VPC levels, and CVD risk. 
Samples were adjusted for age, gender, BMI, cigarette smoking, median household 
income, and 24-hour PM2.5. GLMs that assessed VPCs as the dependent variable utilized 
the gamma probability distribution and the log link function. GLMs that assessed the sum 
of risk factors utilized the normal probability distribution and the identity link function. 
 
 
Table 18. Association between roadway proximity and VPC levels in people with a 
residential duration of at least 6 months. 
Samples were adjusted for age, gender, BMI, cigarette smoking, median household 
income, and 24-hour PM2.5. GLMs that assessed VPCs as the dependent variable utilized 
the gamma probability distribution and the log link function. Cancer patients (n=6) were 
excluded from this analysis.
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OVERALL DISCUSSION 
Highlights 
These chapters describe how VPC levels are associated with CVD risk and 
environmental pollution exposure. In the first chapter, it was determined that VPC levels 
are associated with increased CVD risk, possibly through recruitment in thrombosis and 
suppression in inflammation. Previous investigators reported mixed results in describing 
the associations between risk and VPC levels. Because VPCs are a heterogeneous 
population containing cells of different angiogenic potential, investigation of the large 
panel of VPCs in the current study more accurately described which VPCs sub-
populations are associated with increased CVD risk in an at-risk population. In the 
second chapter, it was described that the acrolein metabolite, HPMA, was associated with 
reduced VPC levels: suggesting that exposure to acrolein is associated with decreased 
VPCs. Additionally, HPMA was associated with increased thrombosis and increased 
FRS. The associations between acrolein exposure and VPC levels and thrombosis had 
been demonstrated in mice, but not in humans. In the final chapter, individuals who lived 
closer to a major roadway had a higher number of risk factors for CVD and higher VPC 
levels. This was a novel assessment in the field and the findings suggest that VPC levels 
are increased as a means of vasoprotection in either roadway exposure or increased CVD 
risk, or both. Ultimately, these investigations revealed that environmental pollution 
exposure is associated with VPC levels, which may also contribute to CVD risk. 
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Strengths 
Population size 
There are multiple strengths of these investigations. First, there was a large 
population recruited for this study, ranking us among the largest VPC investigations of 
at-risk individuals. Many investigations of VPCs and CVD risk have investigated 
associations in less than 100 people 
52, 63, 65, 67, 69-72, 122, 123
. Most of these investigations 
utilized a case-control design. The current study utilized a cross-sectional design, which 
requires more study participants for more strength of association. Werner et al. 
investigated a large population (n=507) using a prospective cohort 
74
.  Kunz et al. 
investigated a cross-section of 122 patients undergoing diagnostic cardiac catheterization 
 
66
. Xiao et al. investigated a cross-section of 574 low-risk individuals 
64
. The current 
study includes a population of 240 individuals (189 with VPC levels) with risk factors for 
CVD. The current study was statistically powered to detect associations with VPC levels. 
With an effect size of 20%, 10 predictors, and statistical significance of 0.05, there is a 
1% chance that our conclusion that VPC levels are associated with CVD risk factors and 
environmental exposures is invalid and they are actually not associated. 
Susceptible population 
Previous research of vascular progenitor cells and the association with CVD risk 
have included both healthy and unhealthy individuals, in terms of CVD risk. The 
environmental investigation of VPCs and risk, however, investigated VPC levels in 
healthy young adults 
30
. It is important to add to the literature an investigation of 
susceptible individuals and their VPC levels associated with environmental exposures. 
Older individuals are more susceptible to the effects of environmental exposures. In 
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addition, older individuals are more likely to have heart disease. Moreover, patients with 
heart disease may be more susceptible to the effects of environmental exposures 
38
. 
Investigating a susceptible population that includes both older individuals and a 
population who have heart disease allows for greater understanding of cardiovascular 
risks of environmental exposures, determined through VPC levels.  
Antigenic markers 
The current study used antigenic markers CD31
+
, CD34
+
, CD45
+/dim
, and 
CD133
+/–
 to define VPCs. These markers are useful in defining circulating VPCs. Some 
previous investigations used markers which were not highly specific to VPCs, including 
1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate labeled acetylated 
low-density lipoprotein (DiI-Ac-LDL) and lectin. In addition to using validated antigenic 
markers, the current study also verified that selected populations were positive for the 
transcription factor inhibitor of DNA binding 1, Id1, indicating that they are endothelial 
progenitor cells.  
VPC measurement 
Some previous studies investigated VPCs using culture and colony forming unit 
assays. These assays are beneficial in determining the growth and functional capacity of 
VPCs 
64, 65
, however, they are less suitable in determining levels of circulating VPCs. The 
current study quantifies VPCs using flow cytometry, a superior method for circulating 
VPC identification and quantification. Additionally, flow cytometry allows for multiple 
measurements with rapid speed. This methodology is beneficial for future clinical use of 
VPC quantification. If a proper cell type is identified to be useful in detection of CVD, 
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the clinical staff will be able to have flow cytometry results, using the current study’s 
methodology, within hours.  
VPC population specificity 
VPCs are a heterogeneous population of cells with different angiogenic potential. 
The current study measured 15 antigenically distinct populations of VPCs. Results from 
this investigation have scientific significance because of the determination of specific cell 
types and sub-populations that are associated with CVD risk and environmental 
exposures. O’Toole et al. determined that CD31+/34+/45+ cells are inversely associated 
with PM2.5 exposure  
30
. The current study also determined that CD31
+
/34
+
/45
+
 cells were 
inversely associated with HPMA, but the results also demonstrated that a sub-population 
of those cells were also inversely associated, CD31
+
/34
+
/45
+
/AC133
–
: suggesting that 
depletion of the late progenitor (AC133
–
), rather than the more immature progenitor cell 
population (AC133
+
), drives the association demonstrated in CD31
+
/34
+
/45
+
 cells. By 
assessing a large number of VPCs, in some cases a more specific marker population that 
is affected can be determined. This is beneficial for future mechanistic investigations, 
allowing for future investigations to be targeted at more specific cell types, and for 
greater understanding of which cell differentiation state is influenced by pollution 
exposure and CVD risk.  
Minimizing exposure misclassification 
To reduce exposure misclassification, multiple efforts were employed including 
the use of biomarkers. Measuring urine HPMA concentrations allows for a reliable 
measure of individual acrolein exposure. Estimating acrolein exposure using ambient 
monitoring would not provide as much benefit if used instead of metabolism 
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quantification because estimates would be more specific to a community rather than an 
individual and the difficulties in determining the amount of time individuals are exposed. 
HPMA is the primary urine metabolite of acrolein, and it is specific to acrolein exposure 
46
, making it the most reliable marker to quantify acrolein exposure. With this 
measurement, the current study was able to determine the HPMA levels of a person at the 
timing that coincides with the timing of the individual’s VPC and cotinine levels. This 
way, the snapshot of exposures occurs at the same time of the outcome measure, VPCs. 
Cotinine was also a biomarker utilized in the current study to reduce exposure 
misclassification in self-reported smoking. Additionally, cotinine is a continuous variable 
that allows quantification of the exposure to tobacco smoke. It accounts for both primary 
and environmental exposure to tobacco smoke. 
Exposure misclassification in the association between VPCs and distance to a 
major roadway was minimized through including only individuals who had a residential 
duration at their current home of at least 6 months. This reduced attributing long-term 
exposures to persons with short-term residency.  
Limitations 
Convenience sample 
The results of the current study are valuable because they add knowledge about 
the association of environmental exposures with VPC levels, which may contribute to 
CVD risk. These associations were determined in a population with increased risk factors 
for CVD, which poses a limitation in being able to generalize the results to the whole 
population. Each participant was recruited during cardiology clinic visits, therefore, their 
clinic visit was related to cardiology concerns. This implies that the population has poor 
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cardiovascular health. Additionally, when reviewing our population characteristics, 
24.6% (n=59) of the study population were primary preventive patients, and 75.4% 
(n=181) were secondary preventive patients, indicating that 75% of the participants had 
overt CAD. For these results to be generalizable beyond a high-CVD risk population, 
more people who are low-risk must be included in the population. A comparison 
population with 1 or less risk factors would be ideal to include for understanding the 
differences between VPC levels among risk scores and risk factors.  Future direction 
should include age- and sex-matched controls with no additional risk factors (outside of 
age and gender).  
Recruitment 
In addition to the convenience sample from the cardiology clinics posing a 
possible limitation, recruiting a sample population that is representative of the clinic 
patient demographics may be another limitation. The population of the current study may 
not entirely represent the clinic population demographics. For example, none of the 
recruiters for the current study fluently spoke any languages other than English; 
therefore, participants who were not English-speaking and did not have a translator 
present could not participate in the study. Possibly as a result, only 1.7% (n=4) 
individuals in the current study were Hispanic. 
It is estimated that 75% of the individuals that were recruited enrolled in the 
study. Many of those that did not enroll explained that they had time limitations, were 
uncomfortable with the biological sample collection, or were not interested. At the onset 
of the study, limitations included retaining study participants after the questionnaire 
administration to provide biological samples following their appointment. Initially, the 
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recruiters would ask patients to meet them at the phlebotomy lab immediately following 
their appointment for biological sample collection. This had poor retention outcomes 
because some patients were unable to locate the lab, some may have forgotten, and some 
may have changed their minds about providing samples. The current study was able to 
change this trend by increasing the number of recruitment personnel and assigning 
recruiters to specific patients and escorting them to the lab to provide samples. An 
additional challenge involved individuals that had “rolling” veins or veins that were 
difficult to locate. In these scenarios, multiple sticks may have been required for an 
adequate blood draw, adding to the patient’s discomfort.  
Misclassification 
Measuring cotinine levels to minimize exposure misclassification in tobacco 
smoke exposure provided a strength in the study by allowing for quantification of smoke 
exposure. Ironically, it also provided as an additional means for exposure 
misclassification. In some assessments, smoke exposure was associated with an outcome, 
but cotinine was not: although self-reported smoking and cotinine were highly correlated. 
If, for example, a study participant reported that they were a smoker, but had not had a 
cigarette in 20 hours, their cotinine levels may represent a non-smoker’s cotinine level.  
Assessing only the population with a residential duration of at least 6 months was 
a great step toward reducing exposure misclassification. Narrowing the population to the 
individuals with at least 6 month home ownership, however, may have misclassified 
renters in the study population. If a renter has been in their current home for more than 6 
months, but the property owner changed less than 6 months prior, they would have been 
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misclassified. If, on the other hand, renters had recently moved to the property, but the 
owner had not changed, their exposure measurement would also be misclassified. 
Determining whether or not an individual was a smoker may have possibly led to 
misclassification. Some study participants indicated that they were current nonsmokers, 
but had only quit smoking weeks prior to the questionnaire. Additionally, some 
individuals described themselves as current smokers, but only smoked a few cigarettes a 
week or just socially. Some investigations only consider individuals to be nonsmokers if 
they have abstained for 6 months. Because of the difficulties in quantifying exposure, we 
also measured cotinine levels.  The difficulty in quantifying smoke exposure is similar to 
other variables in the current dataset including alcohol consumption and exercise. Instead 
of quantifying the amount of exercise or alcohol, these variables were entered as 
dichotomous data, possibly leaving heavy consumers of alcohol in the same category as 
individuals who consume infrequently. 
Outcome measurement 
Some patients were not able to provide blood samples that were needed to 
measure VPCs. Patients that had engaged in past intravenous drug use that caused their 
veins to be damaged (or others that were not able to provide samples from their arm) 
occasionally provided blood samples from their hands, which may have resulted in 
slower blood flow into the vacutainer tubes. The cell preparation tube (CPT) separator 
vacutainer required 8 mL of blood for VPC measurement; some patients were not able to 
provide this amount, possibly resulting in cell levels that were too low to be counted by 
the flow cytometer. 
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There is potential bias in the measurement of VPCs. Although the operator was 
blinded to the disease status and risk factors of the patient, it could have been assumed 
that most study participants are diseased because of their recruitment from cardiology 
clinics. This may have influenced the flow cytometric interpretation through operator 
bias. Additionally, the gating of cell properties in flow cytometry can appear somewhat 
arbitrary and possibly differ from investigator to investigator. Therefore, one investigator 
directed and verified the gating for consistency. Additionally, the CD31
+
 antigenic 
marker is considered to be less specific in indicating the endothelial phenotype than the 
kinase insert domain receptor (KDR
+
) (vascular endothelial growth factor receptor-2
+
 
(VEGFR-2
+
) is also known as KDR
+
). To address not marking for KDR
+
 rather than 
CD31
+
, we verified the endothelial progenitor cell phenotype with the presence of Id1
+
 
cells that were CD31
+
. 
VPCs are useful to investigate because they are specific to the vascular and 
cardiovascular systems and are sensitive to environmental exposures. It is important to 
control for many factors in human VPC assessments because many factors influence 
levels of circulating VPCs. Gender influences VPC levels; VPC levels fluctuate during 
the menstrual cycle in women. A study limitation is that the current investigation did not 
account for what phase of menstruation female participants were undergoing. To account 
for this, the current study stratified by gender to determine whether associations changed, 
and the direction of associations did not change. Additionally, differences were compared 
between VPC levels among genders, and no significant differences were found between 
VPC levels and gender. Models in the current study were adjusted for gender to account 
for any undetermined differences between men and women (except models with FRS or 
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FRS category because gender is weighted in the risk score). Additionally, exercise 
influences VPC levels by mobilizing VPCs from the bone marrow into circulation. The 
questionnaire item for exercise was not robust enough to adequately quantify exercise 
within the study population. Adjusting the models for exercise did not appear to provide 
additional benefit over adjusting for BMI, in terms of statistical significance. Therefore, 
BMI (a continuous variable) was entered into the selected adjusted regression models. 
BMI provides an additional limitation in that it has been reported that waist 
circumference and waist-to-hip ratio are more closely related to adverse cardiovascular 
health 124, 125. 
An additional limitation in the outcome measurement is the lack of adjusting our 
analyses for multiple comparisons. Associations between each VPC and the exposure and 
risk factor were assessed individually, one model for each VPC – 15 total. The current 
study investigated each cell separately to understand the associations between each VPC 
and the exposures and risk factors individually. If there is a 5% chance of error for each 
model, this increases the likelihood that there will be an association determined within 15 
models that is erroneous. 
CVD risk/ exposure measurement 
A crude measure of risk included in our assessments was the “sum of CVD risk 
factors” variable. This variable allowed for greater understanding of how increases in 
cumulative risk factors are associated with VPC levels. This measure is less valid to 
assessing risk because it does not weight for different risk factors. Ultimately, CVD risk 
is predicted by the FRS and FRS category in the current study. The FRS predicts future 
myocardial infarction and cardiac mortality. Some criticism of the FRS is due to the 
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original study cohort being unrepresentative of the general population: completely 
Caucasian and middle class. The Framingham Heart Study now includes multiple 
ethnicities in its subsequent cohorts 
126
, and the FRS has been validated against other 
ethnicities 
127
. Additional criticism of the FRS involves the lack of accurate prediction for 
women and individuals in the intermediate risk category (FRS 10 – 20) 22. This poses a 
limitation where women and individuals with intermediate risk may not have an 
appropriate risk score. In fact, cardiovascular events can occur without an individual 
having any Framingham risk factors. The Reynolds Risk Score (RRS) is another risk 
algorithm predicting risk of adverse cardiovascular outcomes. The RRS predicts heart 
attack, stroke, coronary revascularization, and cardiovascular death. It was derived to 
better estimate risk in women and intermediate risk populations. The RRS includes 
Framingham risk factors (age, hypertension, hyperlipidemia, diabetes, smoking, and 
gender) along with family history and C-reactive protein (CRP). The current study was 
unable to investigate the RRS due to incomplete family history data. Investigating risk in 
terms of the RRS in its association with VPC levels will be a beneficial and novel 
approach in future assessments. Because the current investigation determined that VPC 
levels were inversely associated with hsCRP in an at-risk population, it would be 
interesting to understand the association with the RRS. Ultimately, the RRS may be a 
better predictor of VPCs suppressed in inflammation, while the FRS may better predict 
VPCs recruited in thrombosis. More research would be required to investigate the 
potential associations. 
Additional cardiovascular risk scores that may provide added benefit in 
understanding the association between VPCs and risk include the Systematic COronary 
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Risk Evaluation (SCORE), which measures the risk of fatal CVD with an algorithm 
including age, gender, total cholesterol, systolic blood pressure, and smoking 
128
. The 
Prospective Cardiovascular Münster (PROCAM) Study score assesses risk of myocardial 
infarction and cardiac death through an algorithm that includes age, low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, smoking, 
systolic blood pressure, family history, diabetes, and triglycerides 
129
. The Diamond-
Forrester score predicts significant CAD through age, sex, and chest pain 
130
. Because 
these scores measure different outcomes, their association with VPC levels may be 
helpful for greater understanding of the role of these cells in CVD risk. 
HPMA is a marker of acrolein metabolism, but it is not possible to attribute the 
acrolein exposure only to the environment. There are environmental sources of acrolein 
exposure (combustion of fossil fuels, open fire, industrial emissions, vehicular exhaust, 
and tobacco smoke), but there is also endogenous acrolein exposure as well as exposure 
to acrolein in food and alcohol consumption. It is not known what portion of our acrolein 
exposures are endogenous compared to environmental. Therefore, to better estimate 
environmental acrolein exposure, in addition to HPMA levels, it would have also been 
beneficial to have ambient acrolein levels as well. Personal samplers would be best 
because they would remain with a person wherever their daily activities lead them. 
However, these additionally provide limitations because individuals may not wear them 
properly or wear them at all. Some find these uncomfortable, and they are an added 
expense for the investigator. In-home monitors would also be beneficial, but that may not 
be where the participants spend most of their time. There are also complaints of the noise 
and space they impose. Ambient air monitoring stations throughout the study area would 
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be beneficial, but there are not enough acrolein monitors distributed widely across 
Jefferson County, KY to provide a valid estimation of such a volatile chemical.  
Roadway proximity studies operate with the assumption that study participants 
spend a majority of their time at home. A better estimation would involve geocoding the 
distance to roadway of both the home and work addresses and accounting for the time 
spent at both. Additionally, inclusion of a variable that accounts for efficiency and 
insulation in homes, possibly estimated by the age of the home, would provide benefit in 
attributing exposures. 
Future Directions 
Because of the multiple implications of examining whether a population with 
increased CVD risk has vascular progenitor cell levels that are associated with CVD risk 
and environmental exposures, there are many directions in which the current study results 
can be expanded and applied. The results of the current study should be assessed in 
animal models. Mechanistic explorations in animals will add greater understanding of the 
associations between the environment and CVD risk, detected by VPC levels.  
One key goal is to determine the best VPC population to be measured in a clinical 
setting for diagnostic purposes in CVD. As described before, VPC levels can be 
quantified within hours, allowing for a quick turn-around on information. Future 
investigations should determine whether VPC levels provide additional benefit to 
determining risk in the population within the intermediate FRS category (FRS 10 – 20). 
Understanding which VPC populations are associated with specific risk factors will be 
helpful in determining targets for therapeutic interventions. Determining, for example, 
the VPC population associated with hypertension will allow for future investigations that 
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mobilize these VPCs in hypertensive patients. In the current study, VPC levels are 
suppressed in patients with inflammation. Future investigation of mechanistic means to 
increase VPC-5 (CD31
+
/AC133
+
) in patients with inflammation may minimize or prevent 
vascular damage, improving patient cardiovascular outcomes. 
In an effort to determine populations that are most associated with risk, we 
divided the cell populations into groupings based on the single antigenic markers and 
possible sub-populations. Possibly because there is much overlap between the cell 
populations and many are correlated with each other, we did not find trends in 
associations on this basis (with the exception of VPCs and proximity to a major 
roadway). Future directions should consider the antigenic marker similarities common to 
the risk factor or exposures and develop hypotheses on that basis to guide future 
understanding. 
Because it has now been determined that VPCs decrease in humans exposed to acrolein, 
understanding the mechanism of VPC depletion in animals will give better understanding 
of the role of acrolein exposure in vascular damage. Because the population living closer 
to the roadway had a higher number of risk factors and higher number of VPCs, future 
investigations should explore whether the VPCs are increased in the population living 
closer to the road because increased CVD risk results in these cells being mobilized into 
circulation, environmental insults are stimulating VPC mobilization, or both. 
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OVERALL SUMMARY 
Taken together, these chapters describe how environmental pollution exposure is 
associated with VPC levels, contributing to CVD risk. In the first chapter, the objective 
was to describe the associations between VPC levels and cardiovascular disease risk. 
VPCs in circulation are suspected to be a sensitive indicator of cardiovascular health. 
Several investigators have suggested that circulating VPC levels are decreased in 
populations with CVD; however, some positive associations with CVD have been 
demonstrated. Likely reasons for the mixed results may be due to the use of cellular 
definitions that were non-specific to VPCs and assays not specific to quantifying 
circulating levels of these cells. Therefore, the current study evaluated the relationship 
between CVD risk and VPC levels using antigentically defined VPCs with angiogenic 
potential. CVD history and risk factors, blood, and urine were collected in a cross-
sectional assessment of 240 patients in the Louisville, KY Healthy Heart Study receiving 
primary or secondary preventive treatment for CVD. Fifteen VPC populations measured 
in peripheral blood using VPC-specific antigenic markers of CD31
+
 (endothelial cell), 
CD34
+
 (stem cell), CD45
+/dim
 (hematopoietic/ non-hematopoietic), AC133
+/–
 (early/ late 
progenitor cell) were quantified using flow cytometry. Generalized Linear Modeling 
(GLM) techniques were utilized to describe associations between VPC levels, traditional 
CVD risk factors, the Framingham Risk Score (FRS), plasma levels of fibrinogen, and 
platelet mononuclear cell aggregates in whole blood (markers of thrombosis), and serum 
levels of high sensitivity C-reactive protein (hsCRP; a marker of inflammation). FRS 
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category was inversely associated with VPC-5 (CD31
+
/AC133
+
) and positively 
associated with VPC-3 (CD31
+
/34
+
/45
dim
/AC133
+
), VPC-13 (CD34
+
/AC133
+
), and VPC-
15 (CD34
+
/45
dim
/AC133
+
). Fibrinogen was positively associated with VPC-1 
(CD31
+
/34
+
/45
dim
), VPC-3, VPC-13, and VPC-15. Platelet mononuclear cell aggregates 
were positively associated with VPC-6 (CD31
+
/34
+
), VPC-9 (CD34
+
), and VPC-14 
(CD34
+
/45
+
/AC133
+
). HsCRP was inversely associated with VPC-5 and VPC-11 
(AC133
+
) levels. These results suggest that VPC-5 levels decrease as risk increases, 
possibly through suppression during inflammation. Results also indicate that VPC-3, 
VPC-13, and VPC-15 increase as risk increases, possibly due to their role in resolving 
venous thrombus. Results from this investigation described how VPC levels are 
associated with CVD risk in a population at increased risk for CVD. Future direction 
from the current investigation should involve the verification of these results in animal 
models to understand the mechanism behind these associations. Additionally, future 
planned research will investigate these associations beyond an at-risk population. 
In the second chapter, the association between acrolein exposure and VPC levels 
was assessed to understand how the environment contributes to CVD risk. Combustion 
pollutants, including acrolein, are associated with decreased VPC levels in mice; 
however, this was the first investigation of the association between acrolein exposure and 
VPC levels in humans. To estimate acrolein exposure, the primary urine acrolein 
metabolite HPMA was quantified using gas chromatography / mass spectrophotometric 
analysis (GC/MS). Additionally, urine levels of the nicotine metabolite, cotinine, were 
determined by GC/MS. The associations between HPMA concentrations and smoking, 
VPC levels, the FRS, and the markers of thrombosis and inflammation were assessed 
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using GLM techniques. HPMA levels were positively associated with tobacco smoke 
exposure. After adjustment for traditional risk factors and potential confounders, VPC-2 
(CD31
+
/34
+
/45
+
), VPC-8 (CD31
+
/34
+
/45
+
/AC133
–
), VPC-11, and VPC-14 were inversely 
associated with HPMA. Platelet mononuclear cell aggregates were positively associated 
with HPMA. The FRS and FRS category were positively associated with HPMA. VPC-2, 
VPC-8, VPC-9, and VPC-14 were inversely associated with HPMA after stratification for 
non-smokers. The major finding of this study is that exposure to acrolein is associated 
with vascular outcomes, determined through reductions in circulating levels of VPCs. 
Additionally, as acrolein exposure increases (detected by acrolein metabolism), a marker 
for thrombosis (platelet mononuclear cell aggregates) and CVD risk increase. 
Implications of these results are of added value because the current study found these 
associations in a population with increased risk for CVD, a population more susceptible 
to the effects of environmental exposures.  
The third chapter presented the association between proximity to a major roadway 
and VPC levels as an added analysis in understanding the environmental contribution to 
VPC levels and CVD risk. A substantial body of research has established that living in 
close proximity to a major roadway is associated with increased CVD morbidity and 
mortality; however, this is the first investigation of the impact of exposure to traffic 
pollution on VPC levels. Vehicular exhaust is a source of acrolein exposure, and distance 
to roadway is a common measure of exposure to traffic-related pollution. The objective 
was to investigate the association between residential proximity to a major roadway (an 
indicator of traffic pollution exposure) and circulating VPC levels indicating CVD risk. 
Residential addresses were geocoded in a Geographic Information System (GIS), with 
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major roadways defined as roads carrying an annual mean of 5,000 or more vehicles/ day. 
Individuals were considered exposed if they resided within 50m of a major roadway. The 
association between roadway proximity and VPC levels, CVD risk factors, the FRS, and 
markers of thrombosis and inflammation was assessed using GLM techniques, and the 
models were adjusted for traditional covariates along with potential confounders. Only 
the population with a residential duration of at least 6 months was included in the final 
analysis. A large portion of study participants resided in the northwestern portion of 
Jefferson County, KY, called, “West Louisville,” which has disproportionately high CVD 
mortality rates and environmental exposures. Levels of VPC-4 (CD31
+
/34
+
/45
+
/AC133
+
), 
VPC-5, and VPC-14 were significantly higher in the population in close proximity to the 
roadway after adjustment for potential confounders. VPCs with the AC133
+
 (early 
progenitor cell) marker were higher in people who lived closer to a major road, 
suggesting that the effects of traffic pollutants on the vascular system result in increased 
circulation of early (immature) progenitors as a means of vasoprotection. Because the 
population living closer to the roadway had a higher number of risk factors and higher 
VPC levels, future investigations should explore whether the VPCs are increased in the 
population living closer to the road because increased CVD risk results in these cells 
being mobilized into circulation, environmental insults to the vasculature are stimulating 
VPC mobilization, or both. 
Taken together, these chapters describe an important aspect of the influence of the 
environment on CVD risk, assessed by VPC levels. The first chapter is significant 
because it accurately defined VPC populations to assess potential VPC associations with 
CVD risk factors in a population at increased risk for CVD. The second chapter expanded 
 
 
110 
scientific knowledge through quantifying individual levels of the primary acrolein 
metabolite to determine its association with adverse cardiovascular health in humans, a 
novel investigation. The third chapter advanced the field of environmental cardiology by 
evaluating the established association between roadway proximity and CVD risk through 
investigation of VPC levels, a novel assessment in the field. Results of these 
investigations provide insights for future mechanistic assessments of VPCs, and add 
additional information to drive future investigations for VPCs in interventional therapies 
for CVD risk factors and environmental exposures. 
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